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SUMMARY 
 
 
 
 
Human papillomaviruses (HPVs) are small non-enveloped viruses with a double-stranded DNA 
genome that infect cutaneous or mucosal squamous stratified epithelia of different body sites. They 
can establish aysintomatic infections that usually remain latent in healthy individuals but may also 
be responsible for the development of benign or neoplastic proliferative lesions, depending on the 
specific oncogenic properties of the different type of virus involved.  
To date, more than 150 HPV types have been completely sequenced and classified into five 
genera based on phylogenetic analyses. These display a variety of different epithelial tropisms and 
life-cycle strategies, of which, the Alpha genus (α-HPVs) is the best characterized and comprises 
mucosa-tropic types associated with the development of genital cancer (e.g. HPV 16, 18).  
HPVs belonging to the skin-tropic Beta genus (β-HPVs, e.g. HPV 5 and 8) appear to cause 
widespread unapparent infections without associated disease in the general population.  
In patients with epidermodysplasia verruciformis (EV; an inherited primary immunodeficiency 
characterized by a high susceptibility to active β-HPV infection), β-HPVs replicate very efficiently 
and reveal their full transforming potential, inducing disseminated wart-like lesions and driving 
their progression to non-melanoma skin cancer (NMSC). Their involvement in skin carcinogenesis 
in both immunocompetent and non-EV immunocompromised patients is unclear, as both 
epidemiological and molecular evidences often conflict and are inconclusive. However, it is thought 
that, at least in conditions of impaired immune function (resulting from either primary or acquired 
immunodeficiency) β-HPVs might reactivate and contribute to the pathogenesis of NMSC, whose 
incidence is greatly increased in immunosuppressed individuals compared to the general population 
(Doorbar et al. 2012; Akgül et al. 2006; Aldabagh et al. 2013)  
 
Solid organ transplantation is a treatment offered to an increasing number of patients with end-
stage organ diseases; although life-saving, it is associated with an increased risk of second 
malignancies, presumably as result of the long-term post-transplant iatrogenic immunosuppression. 
Most of these (cancers such as Epstein-Barr virus-associated B-cell lymphomas, Human 
Herpesvirus 8-associated Kaposi’s sarcoma, and Merkel cell carcinoma of the skin, associated with 
Merkel cell polyomavirus) result from reactivated viruses whose oncogenic potential is suppressed 
by immunological reactions in healthy individuals. The most frequent type of malignancy arising in 
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organ transplant recipients (OTRs) is NMSC, and in particular the squamous cell carcinoma (SCC). 
The incidence of SCC in OTRs is estimated to be 60-250-fold as great as in the general population, 
and these post-transplant tumours are often found as multiples (commonly more then 10) and are 
highly aggressive.  
 
 
Almost all the available studies are aimed to investigate the association between β-HPV infection 
and NMSC are mostly based on the detection of the presence of viral DNA in tumor tissues or 
positive antibody responses. Very few studies have addressed whether the viruses are actually 
localized in malignant cells or whether they are replicating and transcriptionally active in the 
context of the lesions. Confirmation of the presence of active virus cancerous lesions would greatly 
strengthen the evidence for an involvement of β-HPVs in the pathogenesis of NMSC. 
It has been shown that detection of viral gene products and viral genome amplification by tissue 
staining procedures can be helpful for the visualization of active HPV infections in associated 
lesions, and that different expression patterns of viral lifecycle markers can be correlated to 
different stages of disease progression. This has been particularly noted in the well characterized α-
HPV infections, and a recent study on skin tumors from EV patients has suggested that expression 
of the viral protein E4 and detection of viral DNA may be exploited as markers of viral activity 
during β-HPV associated skin cancer progression (Aldabagh et al., 2013; Pfister, 2003; Feltkamp et 
al., 2008; Doorbar, 2007; Doorbar et al., 2012; Middleton et al., 2003; Borgogna et al., 2012).  
To date a number of studies have attempted to clarify the mechanism that leads to HPV 
becoming persistent infection and to subsequent lesion formation. The general hypothesis has been 
that lesion formation begins with the infection of a basal stem cell (rather than a basal transiently 
amplifying cell) and that the longevity of the stem cells is a key factor in the formation of a 
persistent lesion, with these cells being a reservoir for the infection. High-risk α-HPV chronic 
infections, characterized by long persistence in the slow-cycling epithelial stem cells in the absence 
of apparent disease, is a condition sine qua non for the development of HPV-associated malignancy. 
Several studies have reported the ubiquitous presence of these β-HPV types on the body surface 
in immunosuppressed individuals and in the general population. Viral burden was greater in sun-
exposed sites (e.g. forehead) than in sun-protected skin when its presence was monitored in plucked 
hairs and skin swabs. HPV appear to establish a reservoir of infection in the follicular stem cells of 
hair bulbs, which are thought to be an immune privileged site protecting them from immune 
clearance and therefore enabling the persistence of multiple β-HPV types. 
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The purpose of this study was to extend observations already made in EV patients to other 
groups of subjects at high risk of developing NMSC. A series of skin lesions from kidney transplant 
recipients were systematically analyzed for the presence of βHPV infection, both at the DNA and at 
the protein level, looking for viral markers of transcriptional activity and replication. Using a 
combination of antibodies raised against the βHPV E4 and L1 proteins, it was possible to visualize 
the completion of the viral lifecycle in some precancerous lesions such as actinic keratosis or at the 
periphery of more advanced disease, in organ transplant recipient.  
With the aim of investigating the influence of viral gene expression on keratinocyte 
differentiation, this study took advantage of a transgenic mice model expressing the complete early 
region of βHPV8. A specific protocol, for characterization of the keratinocyte stem cell populations 
has been established on epidermal whole mount samples of both wild type and transgenic mice. 
Keratinocyte stem cell markers CD34, K15, LGR6, LGR5 and Lrig1 were analysed in correlation 
with the proliferation marker Ki67. 
 
 
These data presented in this study demostrates that β-HPVs are transcriptionally active and 
replicating at site of skin transformation and further reinforces the evidence that these viruses are 
involved in the process of skin carcinogenesis in patients who have undergone organ 
transplantation. Detection of viral markers in premalignant lesions and in the adjacent pathological 
epithelium of high-grade tumors supports the idea that β-HPVs may play a role in the early stages 
of skin transforming processes, probably enhancing the carcinogenic potential of UV damage  
rather than in progression and maintenance of neoplastic disease (Akgul et al., 2006; Feltkamp et 
al., 2008; Pfister, 2003; Aldabagh et al., 2013). Furthermore the analysis of epidermal whole mount 
samples has shown the expansion of the Lrig1+ area in the hair follicles of the transgenic mice 
compared with the wild type littermates. Hair follicle keratinocyte stem cell proliferation was 
demonstrated to be elevated within the Lrig1+ cells, compared to the other keratinocytes stem cells 
populations in βHPV8 transgenic mice. Intriguingly, these data suggest that the presence of the viral 
gene may influence normal keratinocyte differentiation, and identifies the specific keratinocyte stem 
cell population that is positive for the Lrig1 marker in the β-HPV8 in vivo model as a possible 
target. .  
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INTRODUCTION 
 
 
 
 
Papillomaviruses: general characteristics 
Papillomaviruses are small, unenveloped, double-stranded, circular DNA viruses exhibiting 
icosahedral symmetry. The papillomavirus genome ranges from 6953 bp [Chelonia mydas 
papillomavirus type 1 (CmPV1)] to 8607 bp [Canine papillomavirus type 1 (CPV1)] in length, and 
have been isolated and characterized from reptiles, birds, marsupials, and multiple other 
mammalian. This wide spectrum in the host species suggests an evolutionary history spanning more 
than 300 million years. They are species-specific and exhibit a strict tropism for the squamous 
stratified epithelia where they can induce cutaneous and mucosal hyperplastic lesions; some PVs 
have also been implicated in the development of epithelial malignancies, especially cancer of the 
uterine cervix and other tumors of the urogenital tract. 
Human Papillomaviruses (HPV) can infect different body sites, such as the upper respiratory, 
oral and genital mucosae and the skin according to the specific tropism of the different viral species. 
They typically establish persistent infections which can either remain in an unapparent silent status 
or either cause clinical manifestations after a latency period of variable duration. The various types 
of epithelial disease that HPVs cause appear linked to their different strategies of transmission and 
propagation within the epithelium, and probably also to their different interactions with the immune 
system. HPVs can be responsible not only for benign hyperproliferative lesions (papillomas) in 
mucosal and cutaneous sites, but also for malignancies (especially squamous cell carcinoma, SCC). 
The specific association of HPV type 5 (HPV-5) with skin cancer of epidermodysplasia 
verruciformis (EV), a rare genetic disease, provided the first molecular evidence for the role of 
HPVs in human cancer. 
HPVs have been implicated in cancers at several sites; in particular, the best documented HPV 
oncogenic activity concerns cervical cancer, on the basis of a meta-analysis of 1 million women 
with normal cervical cytology, around 291 million women worldwide are estimated to have human 
papillomavirus infection of the cervix at a given point, corresponding to an average prevalence of 
10·4%, though prevalence is higher in women younger than 25 years (16·9%). Human 
papillomavirus types 16 and 18 account for roughly 70% of all cervical cancer. 
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Although the causal association of HPV infection with cervical carcinogenesis is epidemiologically 
and experimentally ascertained, its implication in the development of precancerous skin lesions that 
can evolve to high-grade tumors of epithelial origin – comprehensively grouped into the 
histological classification of non-melanoma skin cancer (NMSC) – has been much less clear to date; 
such uncertainties partly come from the fact that cutaneous HPVs have been shown to be 
ubiquitously present in the skin in the general healthy population. Nevertheless, several 
epidemiologic and experimental evidences are in favor of their potential oncogenic role in the 
insurgence of skin lesions (Knipe and Howley 2007; Doorbar 2005; Doorbar et al. 2012; Akgül, 
Cooke, and Storey 2006; Pfister 2003; Burk 2014; Van Doorslaer 2013)  
 
 
Classification and tropism 
Historically, PVs were classified together with the polyomaviruses as a single family, the 
Papovaviridae. This grouping arose because, although PV genomes and capsids are larger than 
those of polyomaviruses, the viruses share many features, including a double-stranded circular 
DNA genome, an icosahedral capsid composed of 72 pentamers, a nonenveloped virion, and the 
nucleus as the site of viral replication and virion assembly. Sequencing of PV genomes, however, 
indicated that, although PV share a common genetic organization, they differ from that of 
polyomaviruses and have no major sequence homology to polyomaviruses, and PV transcription is 
unidirectional, in contrast to the bidirectional transcription of polyomaviruses. Recognition of these 
differences, and others, have led to PV being designated as a separate family, the Papillomaviridae, 
by the International Committee on the Taxonomy of Viruses (Ethel-michele De Villiers et al. 2004; 
Bernard 2013).  
 
After many years of research and genomic sequencing of thousands of PV isolates, PV 
classification was based on phylogenetic criteria following hierarchical taxonomic levels (family, 
genus, species, types, subtypes and variants). Two PV genomes are recognized as distinct types 
(genotypes) if they share less then 90% identical nucleotides in the most conserved genomic region 
L1 ORF, encoding the major capsid protein. Types were designated by a number, following the 
chronological order of their characterization. The PV taxonomy recently adopted is based on the 
phylogenetic relationship of the L1 ORF of animal and HPVs. Higher-order assemblages are 
considered as a genera (identified by Greek alphabetical prefixes) and lower-order assemblage as 
species (each species identified by the number of the best known type). Genera share less than 60% 
nucleotide identity in the L1 ORF, species within a genus share 60-70%, and types within a species 
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share 71-89%. By this approach, more than 200 PV types have been discovered to date, 
encompassing more than 150 HPV types and 103 animal PV types (Ethel-michele De Villiers et al. 
2004; Mahy and Van Regenmortel 2008; Bernard 2013).  
 
Historically, viral evolution has mainly been considered from a predator–prey perspective. Under 
this model, viral fitness (and thus its evolutionary success) is measured by the viral capacity to 
cause disease in its host. However, papillomaviruses cause benign, mostly unapparent, persistent 
infections in their hosts. In addition, papillomaviruses are highly host-restricted, and cause abortive 
infections in non-host species. In fact, the only exceptions to strict species specificity were 
described in mammalian hosts known to hybridize, thereby challenging the hosts' species definition. 
The observation that papillomaviruses cause benign infections unable to cross the hosts' species-
barrier has led to the hypothesis of “host-linked evolution”. 
The traditional (orthogenetic) definition of co-evolution states that parasites of closely related host 
species should be closely related themselves and cluster together in the parasite phylogenetic tree. 
Furthermore, dates associated with parasite divergence should coincide with the host-species 
divergence. Therefore, any incongruence between both trees should be considered as evidence that 
parasite and host did not co-evolve. 
With an increase in the number of papillomavirus sequences (and their associated hosts), it became 
clear that papillomaviruses and their hosts did not follow an identical evolutionary path. Several 
violations of strict co-evolution can be observed in the phylogenetic tree in Figure 1. For example, 
human papillomaviruses can be found in five different genera dispersed throughout the 
phylogenetic tree. Also, strict co-evolution would place the non-human primate papillomaviruses 
basal to human papillomaviruses, not intermingled as is observed. 
Evolutionary events such as cross-species infection, recombination and virus duplication (e.g. 
following ecological niche adaptation) have been suggested to explain the observed conflicts  
Because of the absence of cross-species infections, it is unlikely that horizontal gene transfer played 
any role in the evolution of the Papillomaviridae. In fact, a study specifically looking at the 
influence of horizontal gene transfer identified only a single potential cross-species transmission 
event. This event involved ancestors of a porcupine (EdPV1) and human (HPV41) papilloma- virus. 
These two viruses are the only members of a divergent genus (Nupapillomavirus). 
A more recent version of the co-evolution theory was initially proposed in the early 1960s. This 
updated theory states that the evolution of parasites follows the evolution of host resources, not the 
evolution of the host species per-se. The shape of the papillomavirus phylogenetic tree could 
potentially be explained using this interpretation of co-evolution. Under this model, specific events 
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in the evolution of hosts (e.g. presence/absence of fur, evolution of sweat glands, etc.) created new 
ecological niches for papillomaviruses to adopt. Therefore, the data suggests a model in which a 
generalist ancestral papillomavirus diverged into four or five increasingly specialized viruses 
(reflected in the 4–5 major clades of the phylogenetic tree). Following these niche adaptation 
events, the virus evolved alongside its hosts. Throughout the co-evolutionary process, the 
availability of new niches would in turn drive viral radiation, followed by further co-speciation. 
In conclusion, the papillomavirus phylogenetic tree cannot be explained solely by co-evolution. 
However, initial niche sorting followed by virus–host linked speciation was a key determinant of 
the papillomavirus evolutionary history (Van Doorslaer 2013). 
 
On the basis of L1 nucleotide sequences, HPVs are distributed in five of the 16 PV genera 
(Figure 1). The Alphapapillomavirus (α-HPV), comprises types differing by their genital, oral 
cutaneous tropism and by their pathogenicity (low-risk types associated with benign proliferations 
and high-risk types associated with invasive carcinomas). The genera Gammapapillomavirus (γ-
HPV), Mupapillomavirus (µ-HPV), and Nupapillomavirus (ν-HPV) comprise types associated with 
cutaneous warts, whereas the types usually associated with EV belongs to the genus 
Betapapillomavirus (β-HPV). 
 
The Alpha genus is the most represented one and comprises both mucosal and cutaneous species. 
 
Infections by mucosal α-HPVs are more common than those by cutaneous α-HPVs and the majority 
of them are asymptomatic. Based on their oncogenic potential and association with the development 
of malignancies, mucosal α-HPVs are further subdivided into low-risk and high-risk groups.  
The World Health Organization has defined 12 mucosal α-HPV types (HPV 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59) as being high-risk cancer-causing types; they are mainly responsible for the 
development of cervical cancer and can also be associated with cancers at other sites with much 
lower incidence (head and neck carcinomas such as oropharyngeal cancers, and cancers of the 
penis, anus, vagina and vulva). Nevertheless, high-risk α-HPVs do not cause cancer in the vast 
majority of the individuals they infect.  
Low-risk α-HPVs cause benign mucosal lesions. Certain types (e.g. HPV 6 and 11) are associated 
with the development of respiratory papillomatosis (especially HPV 11), which is a laryngeal 
disease often occurring in children, and with benign external ano-genital warts (especially HPV 6); 
these types are sometimes occasionally found to be associated with cancers in these sites especially 
in individuals with immune defects, where such infections are more difficult to manage. Other low-
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risk α-HPV types (e.g. HPV 13 and 32) are responsible for the development of oral papillomas as it 
occurs in the case of oral focal epithelial hyperplasia.  
 
Cutaneous α-HPVs (e.g. HPV 2, 3, 7, 10, 27, 28, 57) are associated with the development of 
different types of benign skin warts arising on various sites of the hands, face, elbows and knees.  
 
The Beta genus comprises to date 43 types, which exhibit cutaneous tropism (e.g. HPV 5, 8, 9, 
14, 17, 20, 21, 23, 36, 38, 47, 49). β-HPVs are evolutionarily distinct from the Alpha genus and 
establish widespread unapparent asymptomatic infections that remain latent without any clinical 
manifestation in the general healthy population. In subjects with impaired immune function, it 
seems that these viruses can spread unchecked and they have been implicated in the development of 
NMSC. In particular, in individuals suffering from epidermodysplasia verruciformis (EV), a 
primary immunodeficiency associated with abnormal susceptibility to β-HPV infection, they are 
responsible for the development of disseminated wart-like lesions that often undergo malignant 
progression; there is also increasing body of evidence for their involvement in the onset of 
precancerous skin lesions with potential to evolve to NMSC in other immunosuppressed 
populations (e.g. OTRs, organ transplant recipients). Their involvement in the pathogenesis of 
NMSC in immunocompetent individuals is still unclear. 
 
Gamma (e.g. HPV 4), Mu (e.g. HPV 1) and Nu (HPV 41) genera comprise a smaller number of 
types, exhibiting cutaneous tropism; they are associated with the development of benign palmar and 
plantar skin warts (Ethel-michele De Villiers et al. 2004; Akgül, Cooke, and Storey 2006; Pfister 
2003; Doorbar 2007; Doorbar et al. 2012; Cubie 2013). 
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Figure 1. Papillomavirus phylogenetic tree. The DNA sequence coding for E1, E2, L1 and L2 for all 241 papillomaviruses 
currently on PaVE were downloaded and aligned. A partitioned gene alignment was used as the base for a maximum likelihood 
reconstruction of the phylogenetic treeGenera marked with an asterisk have been proposed to the ICTV, and are awaiting official 
recognition (http://talk. ictvonline.org/files/proposals/taxonomy_proposals_vertebrate1/m/vert01/4244.aspx). The tree is color-coded 
according to presence/absence of the “adaptive proteins”. Red clades lack an E6 ORF. The viruses highlighted in green do not code 
for an E7 protein. The purple clades code for a hydrophobic E5 protein. The Xipapillomaviruses lack an E6 (red), but contain an E5 
(purple)(Van Doorslaer 2013).  
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HPV structure, genomic organization and gene products 
 
The genomes of many of the human and animal papillomaviruses have been sequenced in their 
entirety, and the genomic organization of each of the PVs is similar. HPVs are characterized by 
small (52-55 nm diameter), nonenveloped, icosahedral capsid composed of 72 pentameric 
capsomeres. Their genome is in a double-stranded, covalently closed, circular DNA molecule of 
7500-8000 bp. The viral DNA is associated with cellular histones to form a chromatin-like 
structure. Genomic organization is highly conserved among all HPV family members, with 8-9 
open reading frames (ORFs) on a single transcriptionally active DNA strand encoding a larger 
number of gene products as a result of mRNA splicing (Figure 2). The viral genome is divided into 
three regions: 
- The early region coding for functional proteins (E1, E2, E4, E5, E6 and E7) expressed in all 
the phases of the viral life cycle, which are responsible for the persistence of the viral 
genome in a cell, its replication and the stimulation of cell proliferation necessary to support 
viral replication itself; 
- The late region, coding for the structural coat proteins L1 and L2 that are expressed in the 
final phases of the productive viral life cycle; 
- The long control region (LCR), a non-coding fragment regulating the expression and 
replication of the viral genome (Mahy and Van Regenmortel 2008). 
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Figure 2. The genome organization of the high-risk α-type HPV16 and β-type HPV8. The HPV genome 
comprises a long control region (LCR) and eight genes that are necessary for different stages of the virus life 
cycle. These genes encode a larger number of gene products as a result of mRNA splicing. The LCR 
contains binding sites for cellular transcription factors (e.g., SP1, AP1, Oct1), as well as for the viral E1 and 
E2 proteins that control viral replication and gene expression. The best characterized HPV types have two 
promoter elements (P97 and P670) known as early promoter (PE) and late promoter (PL) that regulate the 
expression of differentially-spliced mRNAs during epithelial differentiation. Specific conserved motifs (M33 
and M29) among the beta-HPVs are shown in the LCR of HPV8 (Lazarczyk et al. 2009). 
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The LCR is a significant non-coding fragment of viral DNA located between the L1 and E6 
ORFs, accounting for about 10% of the entire genome. It contains an origin of replication and cis-
responsive elements for regulatory transcription and replication factors of viral genetic material; in 
detail, there are binding sites for cellular transcription factors (e.g. SP1, AP1, Oct1), as well as for 
the viral E1 and E2 proteins that control viral replication and gene expression (Figure 2). All the 
LCR regions contain enhancers that provide the virus with specific tropism to the stratified 
squamous epithelial cells. Other regulatory enhancer elements are positioned within genes. 
The LCR harbors one of the two well-characterized promoter elements, namely the early promoter 
upstream of the E6 ORF, while in many HPV types the late promoter is located within the E7 ORF 
(Figure 2). These promoters regulate the expression of differentially spliced mostly polycistronic 
mRNAs, being trans-activated in a timely and coordinated differentiation-dependent fashion in 
specific epithelial layers where the different phases of the viral life cycle take place. The early 
promoter mainly drives E6 and E7 expression, while the late promoter regulates the expression of 
all the other viral genes.  
The mRNA species that encode E1, E2 and E4 terminate at the early polyadenylation site and for 
many α-HPVs include E5 as their second or third ORF; transcripts encoding L1 and L2 terminate at 
the late polyadenylation site. The E4 ORF is contained within the E2 ORF, with the primary E4 
gene product (E1^E4) being translated from a spliced mRNA including the E1 initiation codon and 
adjacent sequences. Upon mRNA splicing involving a small portion within the E1 ORF and most of 
the E2 ORF, some high-risk α-HPV types produce the additional gene product E8^E2C. In addition, 
for many HPV types several other spliced transcripts have been reported, encoding variants of the 
early proteins such as N-terminal truncated forms of E2 and E6 (Ciesielska et al. 2012; Doorbar et 
al. 2012; Doorbar 2007; Tommasino 2014; Doorbar 2013). 
 
The papillomavirus major capsid protein, L1, is a ~55 kD protein with the ability to 
spontaneously self-assemble into virus-like particles (VLPs). These VLPs present an exterior 
surface essentially indistinguishable from the native 60 nm non-enveloped papillomavirus virion. 
Purified recombinant L1 proteins can achieve this complex assembly reaction in the absence of any 
chaperones (Schiller and Lowy 2012). Assembled VLPs are potent immunogens, likely due to 
innate B-cell recognition of the regular icosahedrally displayed spacing of surface epitopes 
(Bachmann et al. 1993). These discoveries laid the foundation for the development of the current 
VLP-based vaccines that offer highly effective protection against infection with the cancer-causing 
human papillomavirus (HPV) types 16 and 18. The assembled VLP immunogens used in current 
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HPV vaccines represent the state of L1 in only one phase of the viral life cycle–namely, the rigid 
mature form of the virion during its transmission from one cell to another. In contrast to the mature 
virion state, during the process of virion assembly L1 interactions must be flexible enough to allow 
selective uptake of the viral genomic DNA into the virion lumen. Transmission of some 
papillomavirus species is thought to occur via deposition on environmental surfaces, such that the 
initially fragile immature virion must gain the ability remain infectious in a desiccated state for days 
or longer to achieve transmission (Roden, Lowy, and Schiller 1997). This high degree of stability is 
achieved through a maturation process in which the flexible immature virion gradually achieves a 
more rigid state that is stabilized by disulfide crosslinks between neighboring L1 molecules. Since 
L1 forms the entire exterior surface of the stabilized mature virion, it obviously must mediate initial 
attachment to host tissues or cells. After attachment to cells, L1 must again become pliable enough 
to ultimately allow release of the viral genome into a new target cell (Buck, Day, and Trus 2013). 
 
Similar to L1 the minor capsid protein L2 is a 55KDa protein, and plays major roles in both 
papillomavirus assembly and the infectious process. While L1 forms the majority of the capsid and 
can self-assemble into empty virus-like particles (VLPs), L2 is a minor capsid component and lacks 
the capacity to form VLPs. However, L2 co-assembles with L1 into VLPs, enhancing their 
assembly. L2 also facilitates encapsidation of the ~8kbp circular and nucleosome-bound viral 
genome during assembly of the non-enveloped T=7 d virions in the nucleus of terminally 
differentiated epithelial cells, although, like L1, L2 is not detectably expressed in infected basal 
cells. With respect to infection, L2 is not required for particles to bind and enter in the cells.  
Much of the studies and analysis about L2 are based on HPV16 L2’s primary sequence and these 
mapped domains because unfortunately very little information exists on its higher order structure 
(Wang and Roden 2013).  
 
The E1 protein, an ATP-dependent DNA helicase, is the only enzyme encoded by the PV 
genome. It is tightly regulated in vivo, in particular by post-translational modifications that restrict 
its accumulation in the nucleus. E1 is essential for replication and amplification of the viral episome 
in the nucleus of infected cells. It does so by interacting with cellular DNA replication factors and 
assembling with E2 to the origin of replication to trigger viral DNA replication (Bergvall, Melendy, 
and Archambault 2013). 
The E2 proteins function primarily by recruiting cellular factors to the viral genomes, which 
activate or repress transcriptional processes. The E2 proteins bind specifically to sequence motifs in 
the viral genome and can activate or repress transcription, depending on the context of these binding 
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sites and nature of the associated cellular factors. In particular, it negatively modulates the 
expression of E6 and E7 by down-regulating the activity of the early promoter. Furthermore, E2 
recruits E1 to a specific E1-binding motif in the origin of replication and is implicated in the 
maintenance of the viral genome in its episomal (extrachromosomal) form. It seems to be also 
involved in the regulation of accurate genome partitioning during basal cell division by associating 
to the pericentromeric regions of mitotic chromosomes to drive the tethering of viral episomes to 
the cellular chromatin during mitosis (McBride 2013). 
The E4 open reading frame (ORF) lies within the larger E2 ORF, and varies considerably in size 
between papillomavirus types. In human papillomaviruses, the primary E4 gene product is 
expressed from a spliced mRNA (the E1E4 message). It is the most abundant viral gene product 
and is expressed before L2 and L1. The structure and function being modified, first by kinases as 
the infected cell progresses through the S and G2 cell cycle phases, but also by proteases as the cell 
exits the cell cycle and undergoes true terminal differentiation. E4 is thought to be involved, in 
association with E2, in viral genome amplification and suppression of cellular proliferation in the 
late phases of the productive life cycle; The accumulation to very high levels in the upper epithelial 
layers of the host seems also to be able to disrupt the cellular keratin network facilitating the 
extracellular release of new viral particles (Doorbar 2013). 
 
In the HPVs genome are presents three proteins with transforming properties: the E5, E6 and E7 
oncoproteins. Through combined and cooperative action, they abrogate the activity of tumor 
suppressor factors, promoting evasion of all cell cycle checkpoints and inducing a deregulated 
progression of the cell cycle; they mostly function by associating with and functionally 
reprogramming key components of cellular signal transduction networks. Their activity allows the 
maintenance of S-phase competence and a forced replicative status in the host cell, which is 
essential to the viral life cycle; the result is a stimulation of cell growth, survival and proliferation 
and a delay of terminal cell differentiation. Because of such properties, HPV oncoproteins can 
trigger the initiation and progression of epithelial cancers; in particular, these transforming activities 
are stronger in the case of high-risk α-HPVs, underlying their involvement in the development of 
malignancies. 
 
E5 is the smallest oncoprotein which functionally resembles a viroporin (Venuti et al. 2011). It is 
an 84-aminoacids viral replication protein involved in the early stages of HPV infection. The 
hydrophobic E5 protein localizes to cell membranes (including Golgi, endoplasmic reticulum, 
nuclear membrane) where it may dimerize and trigger cell fusion (Hu et al. 2009). This phenotype 
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is associated with mitogenic signal intensification via E5-inhibited degradation of epidermal growth 
factor receptors (EGFR). However, E5 from dermatotropic α-viruses such as HPV6 or EV- type β-
viruses such as HPV5 does not cause cell fusion, yet retains even stronger affinity for growth factor 
receptors (EGFR, HER2 or platelet-derived growth factor b-receptors) than does HPV16 E5. E5 
also exerts immunosuppressive effects mediated via inhibition of host MHC class II complexes 
and/or reduced cytotoxic T cell recognition of HPV (Campo et al. 2010). These actions could be 
pertinent to the tumorigenicity of HPV16 in the immune-activated niche of the lymphoid tonsil, 
plausibly reducing immune surveillance to the lower levels of the cervix or post-transplant skin. It is 
also possible that the stimulatory effects of E5 on keratinocyte EGFR signaling contribute to the 
epidermotropism of β-HPVs, consistent with the reactivation of E5 signalling seen in some skin 
SCCs containing multiple HPVs (Orth 2006). Still another tumorigenic effect of E5 is to reduce 
expression of the epithelial adhesion molecule E-cadherin, increasing the invasiveness of infected 
cells while driving the epithelial–mesenchymal transition (EMT) (Boulenouar et al. 2010). 
 
E6 and E7 are small proteins, approximately 18 and 13 kDa in size, respectively, and are 
localized in the nucleus. The E6 proteins are also found in the cytoplasm and some studies have 
suggested that E7 also has a cytoplasmic. Are multimeric proteins with potential to associate with 
multiple cellular partners. Such functional differences contribute to the respective transforming 
abilities of various HPV species and types. 
About E7 protein it has been shown to bind zinc and is phosphorylated by casein kinase II (CK 
II). In the best-characterized HPV species, E7 binds and targets for ubiquitin-dependent 
proteasomal degradation the hypophosphorylated form of members of the retinoblastoma tumor-
suppressor family (pRb, p107, p130). In uninfected epithelium, cell cycle entry and cell division in 
the basal and parabasal cell layers is controlled by growth factors that stimulate the activity of G1 
cyclins including cyclinD/Cdk, which phosphorylates Rb family members and displace them from 
transcriptional activators of the E2F family allowing the trans-activation of genes necessary for S-
phase progression. The continual stimulation of these cells physiologically allows renewal of the 
epithelium as surface cells exfoliate. As part the regulated stimulation of this cell cycle entry, 
p16ink4a is up-regulated and forms a compensatory negative feedback loop that suppresses 
cyclinD/Cdk activity, so preventing the over-expression of itself and other E2F-activated genes (e.g. 
MCM, PCNA, Ki67). E7 binds to Rb proteins and displaces them and transcriptional repressors of 
the E2F family from target promoters required for S-phase gene expression without the need for Rb 
phosphorylation and growth factor stimulation; E2F1, 2 and 3 can then occupy these vacant sites 
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and stimulate expression of the host genes necessary for DNA replication and cell cycle 
progression.  
In certain HPV species and types, E7 is necessary for the stable maintenance of HPV episomes in 
epithelial cells. It can stimulate cell cycle progression and subsequent hyperproliferation, induce 
genomic instability, exert antiapoptotic activities, reprogram host cell metabolism and contribute to 
evasion of the local antiviral host immune responses to different extents by a number of other 
mechanisms depending on the specific oncogenic potential. 
The HPV E6 proteins are approximately 150 amino acids in size and contain four Cys-X-X-Cys 
motifs, which form two unusually big zinc finger domains of 29-30 AA, respectively, which are 
important for protein stability and activity. The E6 proteins from the low risk and high risk HPV 
appear to have similar transcriptional activation properties.  
E6 interferes with DNA damage repair, growth arrest and apoptosis. The function of E6 
complements that of E7. The efficient binding of Rb proteins by E7 can lead to inhibited cell 
growth and apoptosis through a p53-dependent pathway; as a result, E6 proteins of many HPV 
types have evolved to target the tumor suppressor p53 for ubiquitin-dependent proteasomal 
degradation or other forms of inactivation, resulting in the abrogation of its activity that plays an 
essential role in protecting genomic integrity. In uninfected epithelium, p53 expression increases in 
response to cellular stress such as DNA damage and induces the expression of p21, which allows 
cell cycle arrest at G1-S checkpoint until errors in DNA replication can be repaired; if DNA damage 
cannot be repaired, p21 activates the expression of proapoptotic genes to prevent the replication of 
damaged DNA. In addition, p53 can also trigger apoptosis upon DNA damage through pathways 
unrelated to its transcriptional activity The consequence of E6 action is the abrogation of all these 
p53-dependent tumor suppressor functions in the infected cells. 
In certain HPV species and types, E6 can inhibit apoptosis by interfering with p53-dependent or 
p53-independent apoptotic pathways through other mechanisms to different extents depending on 
the specific oncogenic potential. 
In any case, E6 inactivates key mediators of stress-induced programmed cell death more or less 
strongly depending on the transforming properties of specific HPV species and types. As a 
consequence, cell cycle arrest and apoptosis in response to E7-mediated cell cycle entry are 
prevented and DNA replication followed by cellular proliferation is promoted in cells with damaged 
DNA because of the disruption of the DNA repair process in the host cells; this events, which are 
more evident in oncogenic HPVs, increase the frequency of spontaneous mutations in the cellular 
genome during replication, favoring the occurrence of genomic instability underlying transforming 
processes. 
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Another important way how E6 proteins of some oncogenic HPVs contribute to transformation is 
the activation of the human telomerase reverse transcriptase promoter, which controls the 
transcription of the catalytic telomerase subunit. 
In high risk HPVs, E6 can also exert transforming activities by inducing host cell immortalization, 
loss of host cell polarity and anchorage-independent growth and altering host cell differentiation 
and metabolism; finally, E6 can facilitate viral escape of the antiviral immune surveillance 
mechanisms (Knipe and Howley 2007; Moody and Laimins 2010; Doorbar et al. 2012; Doorbar 
2007; Akgül, Cooke, and Storey 2006; Ciesielska et al. 2012; McLaughlin-Drubin, Meyers, and 
Munger 2012). 
 
 
HPV life cycle 
 
Irrespective of their evolutionary origin, all papillomaviruses must complete their life cycle in 
the epithelial tissue that they infect (summarized in Figure 3), and produce infectious particles that 
are eventually secreted from the epithelial surface. Human papillomavirus infects cells in the basal 
layer of the epithelium, probably via microabrasions in the epithelial surface. It capitalises on the 
lateral extension of basal cells that accompanies wound healing to gain entry to the cell. 
Infectious internalization takes several hours, after which viral DNA is released from the capsid and 
transported into the nucleus as free genetic material or extrachromosomal episomes. The synthesis 
of new virions occurs only after the infected cell has undergone mitosis and one of the infected 
daughter cells has differentiated. 
HPV replication requires the timely and coordinated expression of the different viral gene 
products as the infected cell moves towards the epithelial surface; this highly regulated pattern of 
gene expression allows the different stages of the life cycle to be completed appropriately. For this 
reason, HPV life cycle takes 2-3 weeks – the time necessary for an epithelial cell to migrate from 
the basal to most superficial layers, mature, undergo senescence and die. Whether a productive life 
cycle is or is not completed depends on the nature of the epithelial site where infection occurs, as 
well as on the presence of external factors such as hormones and cytokines. 
Due to the clear association of high-risk α-HPV types with human carcinogenesis, most of the 
biological studies so far have been focused on these types (Doorbar et al. 2012; Doorbar 2007; 
Tommasino 2014; Crosbie et al. 2013; Moody and Laimins 2010).  
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Figure 3. Productive HPV life cycle. HPVs replicate only in fully differentiating squamous epithelia. The 
life cycle involves both temporal and spatial separation of viral protein expression. The virus first infects a 
cell in the basal layer of the epithelium where access is naturally facilitated (e.g. microtrauma, epithelial 
transitional zones, hair follicles). In the lower proliferative compartments of the epithelium, there is a phase 
of viral episome maintenance al low copy number, in which viral and cellular DNA replicate together. As 
long as the cell is dividing, HPVs control the expression of their viral proteins very tightly; the E6 and E7 
oncogenes are thus expressed at very low levels, along with the genes coding for E1 and E2 replication 
factors. When the host cells stop dividing and begin to differentiate into mature epithelial cells, this provides 
a signal to the virus to activate all of its genes to amplify the viral genome copy number to the thousands. In 
the top layers of the epithelium, all of the viral genes, including those encoding the L1 and L2 proteins, are 
expressed, and many thousands of viral genomes are encapsidated; finally, the newly assembled infectious 
viral particles exit the cells in the context of epithelial surface desquamation. The time taken from infection 
to the generation of new virions is at least 2-3 weeks (Stanley, 2012). 
 
 
Experimental models suggest that infection requires access of virus particles to the basal lamina 
and the interaction with heparin-sulphate proteoglycans and possibly also laminin. Structural 
changes in the virion capsid, which includes furin cleavage of L2, facilitate transfer to a secondary 
receptor on the basal keratinocyte, which is necessary for virus internalization and subsequent 
transfer of the viral genome to the nucleus; although the α-6 integrin and growth factor receptors 
have been implicated in this process, the precise nature of the entry receptor remains somewhat 
controversial.  
Once internalized, virions undergo endosomal transport, uncoating and cellular sorting. The L2 
protein-DNA complex ensures the correct nuclear entry of the viral genomes, while the L1 protein 
is retained in the endosome and ultimately subjected to lysosomal degradation.  
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In many cases, infection is thought to require epithelial wounding or micro-wounding to allow 
access of the virus to the basal lamina, and a role for the wound healing response in simulating the 
lateral expansion of the infected cells has been suggested. Indeed, active cell division, as would 
occur during wound healing, is thought to be necessary for entry of the virus genome into the 
nucleus, and it has been proposed that lesion formation requires the initial infection of a mitotically 
active cell. Given the diversity of HPV types and HPV-associated diseases, is not always possible 
make such broad generalizations regarding the route of infection, as multiple entry pathways have 
been invoked depending on the virus type under study. Some HPV species are thought to infect 
sites where access to the basal layer is naturally facilitated, such as the base of the hair follicle for 
cutaneous HPVs, or sites where columnar and stratified squamous epithelial cells meet each other, 
such as the cervical or anal squamo-columnar junctions for high-risk α-HPVs. For some time now, 
the general hypothesis has been that lesion formation begins with the infection of a basal stem cell 
(rather than a basal transiently amplifying cell) and that the longevity of the stem cells is a key 
factor in the formation of a persistent lesion, with these cells being a reservoir for the infection 
(Doorbar 2007; Doorbar et al. 2012). 
 
Infection of the basal stem cell is followed by initial phase of genome amplification and then by 
maintenance of the viral episome al low copy number (100-200 copies per cell). In benign oral 
papillomas in animals, the basal copy number has been quantified using laser capture methods as 50 
to 100 copies per cell, but it is likely that there will be variation from lesion to lesion and between 
different sites. 
Due to the lacking of the enzyme machinery necessary for viral DNA replication, the viral 
genome amplification depends on the presence of the cellular DNA replication machinery. Thus the 
viral DNA replication follows cellular DNA replication as the cells progress through S-phase.  
The viral replication proteins E1 and E2 are thought to be essential for this initial amplification 
phase, which are expressed from the late promoter and ensure viral DNA replication and 
transcription. It has been proposed that the use of a viral DNA helicase (i.e., E1), which is distinct 
from the cellular replication helicases (MCM proteins), allows viral DNA replication to be 
disconnected from cellular DNA replication during genome establishment and amplification; 
however, at this stage the viral genomes are replicated in synchrony with cellular DNA replication. 
E2 also regulates accurate genome partitioning during basal cell division.  
The precise role of the E6 and E7 proteins in infected basal cells is uncertain, particularly for the 
low-risk α-HPVs and cutaneous HPVs. In these HPV types, the role of the wound healing response 
in driving the initial proliferation of the infected cell(s) may well be critical. In the case of the high-
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risk α-HPV types there is a clear role of the viral E6 and E7 proteins in driving cellular proliferation 
in the basal and parabasal cell layers, where an expansion in lesion size is facilitated.  
Viral proteins are not readily detectable prior to the onset of genome amplification during normal 
productive infection; the low level expression of viral proteins in the basal layer is thought to 
reflect, at least in part, the need of the virus to avoid detection by the host’s immune system 
(Doorbar 2007; Doorbar et al. 2012). 
 
The maintenance of viral genome in the proliferating basal cells, and in cells in the lower 
epithelium, is a common feature of all papillomaviruses.  
The late productive stage of the life cycle, starting with vegetative viral genome amplification 
(around 1000 copies per cell), is triggered as the infected cells differentiates and are pushed towards 
the epithelial surface by the division of the cell beneath. The specific events that induce the onset of 
genome amplification are not well understood, but depend in part on changes in the cellular 
environment as the infected cells move to the upper epithelial layers; of key importance is the up-
regulation of the late promoter, whose activation in cells expressing E6 and E7 leads to an increase 
in the levels of viral proteins necessary for replication, including E1, E2, E4 and E5. After an initial 
increase in viral copy number, the infected ‘differentiating’ cells move from an S-like to a G2-like 
phase, with viral genome amplification occurring primarily in G2 after cellular DNA replication has 
been completed; the virus at this point fully recruits the cellular DNA replication machinery for its 
own replication. 
 
A key function of the E6 and E7 proteins in most HPVs is not to promote basal cell proliferation, 
but rather to stimulate cell cycle re-entry in the mid-upper epithelial layers in order to allow genome 
amplification. These differentiating cells normally would not be replication–competent, since they 
do not naturally express the replicative machinery that the virus depends on; the expression of the 
E6 and E7 proteins in these layers allows the infected cells to aberrantly re-enter S-phase and for 
viral genome copy-number to rise. In high-risk α-HPVs, the stimulation of cell cycle entry occurs in 
the basal layer and above; for unclear reasons, high-risk oncoproteins can also promote the 
proliferation of the infected basal cells, which is important for the induction of neoplasia. 
There is also a need for the viral replication proteins E1 and E2, which increase in abundance 
following the up-regulation of the late promoter. 
In addition to E1 and E2, it is thought that the E4 and E5 proteins contribute indirectly to 
genome amplification success by modifying the cellular environment, with E5 also being involved 
in koilocyte formation.  
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Abundant high-risk E4 can inhibit cell cycle progression during G2-phase, and this leads to cell 
cycle arrest at the G2-M boundary by sequestering these proteins in the cytoplasm. It has been 
suggested that continued expression of E7 in a cell containing abundant E4 might lead to the 
maintenance of an S-phase environment, which allows accumulation of the viral genomes. The 
increase in E2 that is thought to accompany E4 must eventually down-regulate the viral early 
promoter that induces E7 production and entry into S-phase; the steady rise in E2 may act both to 
initiate genome amplification, and in a timely manner, to turn it off once amplification is complete. 
 E5 is also thought to make an important contribution to genome amplification success through its 
ability to stabilize EGFR and to enhance EGF signaling and MAPK activity, thus allowing the 
maintenance of a replication-competent environment (Doorbar 2007; Doorbar et al. 2012). 
 
The late productive stage of the life cycle takes place in the infected cells that undergo terminal 
differentiation in the most superficial epithelial layers. The completion of the life cycle ultimately 
involves the expression of the minor coat protein L2, the exit of the cell from the cell cycle and the 
expression of the major coat protein L1 to allow genome packaging. L1 and L2 are expresses only 
in cells that have already undergone genome amplification and which contain elevate concentration 
of E4 protein in their cytoplasm. This seems to require a change in splice site usage rather than 
promoter activation, leading to transcripts initiated at the late promoter that terminate at the late 
polyadenylation site rather than the early site, an event that is aided by high levels of E2 expression 
and by the presence of negative regulatory elements that destabilize late transcripts and allow the 
preferential synthesis of early transcripts in proliferating cells; furthermore, the pattern of codon 
usage within the late genes is distinct from that of the host cells, and this may further contribute to 
the suppression of L1 expression in the lower epithelial layers. It is thought that the accumulation of 
virion structural proteins to high level is retarded until the cells reach the superficial layers in order 
to limit detection by the host immune response. 
Genome encapsidation involves the recruitment of L2 to regions of replication via E2, prior to 
the expression of L1 and the assembly of the icosohedral capsid in the nucleus. Virus maturation 
occurs in the most superficial, dying keratinocytes, leading to the production of extremely stable 
infectious particles. Although not precisely defined, the abundant E4 protein is thought to contribute 
to virion release and infectivity in the upper epithelial layers, as it organizes into amyloid-like fibres 
that disrupt keratin structure and compromise the normal assembly of the cornified envelope; new 
infectious particles are eventually shed from the epithelial surface as the infected cells exfoliate 
through desquamation (Doorbar et al. 2012; Doorbar 2007). 
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α-HPVs and cervical carcinogenesis 
Cervical cancer is the second most common malignancy among women worldwide, with 
approximately 500,000 newly diagnosed cases each year and about 275,000 deaths annually. 
Despite its worldwide distribution, the frequency of cervical cancer varies considerably, being about 
ten times more common in some countries than in others. About 80% of cervical cancer occurs in 
developing countries, where it is frequently the most common cancer of women, accounting for as 
many as one quarter of female cancers. It occurs less frequently in developed countries. 
The frequency of high-risk α-HPV-associated cervical cancers is of around 30-40 people per 
100000 and over 99% of cervical lesions harbor viral sequences, although the proportion associated 
with specific high-risk α-HPV types is different in different countries and shows demographic, 
ethnic and socio-economic variation. Genital α-HPV infection has a peak of incidence in young 
individuals between 15-25 years of age following the onset of sexual activity and a progressive fall 
with age; over 80% of sexually active women become infected at some stage in their life with one 
or several high-risk and low-risk α-HPV types. 
HPV 16 and 18 cause approximately 50% and 20% of the cases of cervical SCC - arising in the 
stratified squamous cells of the ectocervix - respectively, and both types are equally associated with 
around 35% of the cases of cervical adenocarcinoma – arising in the columnar glandular cells of the 
endocervix and more aggressive.  
HPV associated pre-cancers present as intraepithelial neoplasia and are named after the site: 
cervical intraepithelial neoplasia (CIN), VIN and VAIN (vulval and vaginal intraepithelial neoplasia 
respectively), PIN (penile intraepithelial neoplasia) and AIN (anal intraepithelial neoplasia). 
Cervical intraepithelial neoplasia and are histologically classified for diagnostic purposes according 
to the grade of dysplasia: CIN1 (mild dysplasia), CIN2 (moderate dysplasia), CIN3 (in situ 
carcinoma); CIN1 lesions are low-grade lesions (LSIL, low-grade squamous intraepithelial lesions), 
while CIN2 and CIN3 lesions are high-grade lesions (HSIL, high-grade squamous intraepithelial 
lesions). The accurate identification of lesion grade has prognostic significance, as it has been 
estimated that around 20% of CIN1 will progress to CIN2, and that around 30% of CIN2 will 
progress to CIN3 if left untreated; CIN3 are generally considered to be the direct precursors of 
cervical cancer, and it has been suggested that around 40% of CIN3 lesions will progress to cervical 
cancer in the absence of intervention. In general, more regions with different histological grade can 
be found in the context of a cervical lesion; different high-risk α-HPV types are usually associated 
with discrete areas of disease except at junction regions (where lesions abut or are in close 
proximity) where more than one type may be detected. 
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Most cervical cancers develop in the transformation zone, corresponding to the squamo-
columnar junction; the transitional site where the columnar glandular cells of the endocervical canal 
meet the stratified squamous cells of the ectocervix. The particular susceptibility of the 
transformation zone to cancer onset and progression may also be linked to the increased 
accessibility and proliferation of the basal cell layers at this metaplastic epithelial site, particularly 
around the time of puberty and the onset of sexual activity. In this case, we can hypothesize that the 
primary preferential target cells for high-risk α-HPV infection may be cells close to the squamo-
columnar junction, such as the epithelial reserve cells, which lie immediately underneath the 
columnar epithelium of the endocervix, and eventually form the stratified epithelial layers of the 
transformation zone as the cervix matures. Early acquisition of high-risk α-HPV infections, also 
facilitated by the low levels in antigen-presenting cells in this site, can disturb the metaplastic 
changes occurring at this time in the transformation zone and increase the risk of cervical cancer in 
the future (Yang et al. 2004; Cubie 2013; Doorbar 2007; Doorbar et al. 2012; Tommasino 2014; 
Moody and Laimins 2010). 
 
Viral life cycle deregulation and cancer progression 
The ordered expression of viral gene products that leads to virus particle production is disrupted 
in HPV-associated neoplasia. In cervical disease, where most research has been done, it is generally 
thought that the levels of E6 and E7 expression increase from CIN1 to CIN3; this deregulation of 
early gene expression is accompanied by a concomitant failure to trigger late events until the cells 
are close to the epithelial surface, and in CIN3 genome amplification is often confined to small 
pockets at the most superficial layers. Changes in the timing of viral gene expression are 
accompanied by changes in the levels of the viral proteins, and this is likely to have a key influence 
in determining lesion grade. 
In this scheme, CIN1 lesions typically retain the ability to complete the life cycle and release 
viral particles, showing a lower level of cell proliferation in the basal and parabasal layers. High-
grade lesions such as CIN2 and CIN3 are characterized by the persistence of cycling cells into 
upper layers, and in CIN3 such cells are detectable at the epithelial surface; such lesions represent 
abortive infections in which viral gene expression is not properly controlled, and late events in the 
virus life cycle are not properly supported.  
The elevation of E6 and E7 expression in high-risk α-HPV infection that leads to the CIN2+ 
phenotype predisposes the cell to the accumulation of genetic changes, which increasingly 
contribute to cancer progression. According to this hypothesis, the relatively low levels of E6 and 
E7 present in CIN1 do not compromise the functions of their cellular targets sufficiently to facilitate 
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cancer progression. The viral deregulation seen in CIN2/3+ is also thought to facilitate integration 
of the viral episome into the host cell chromosome, which can further deregulate the expression of 
E6 and E7.  
It is not clear exactly how gene expression from the viral episome can become deregulated in 
early CIN. The viral gene expression may be deregulated by changes in cell signaling as can be 
brought about by hormonal changes, or epigenetic modifications such as viral DNA methylation, 
which may depend on the nature of the infected epithelial cells. The HPV16 LCR contains hormone 
response elements that can be stimulated by estrogen, and there is ample evidence of cooperation 
between estrogen and HPV in the development of cervical cancer. In CIN, it has been reported that 
the LCR is differentially methylated according to disease severity, which suggests that epigenetic 
changes may also regulate gene expression (Doorbar 2007; Doorbar et al. 2012).  
 
In early CIN most HPV genomes persist in an episomal state, whereas in many HSIL they are 
found integrated into the host cell genome (Figure 4). Several studies have shown that the frequency 
of viral DNA integration increases with the severity of the cervical lesion, indicating that this event 
is implicated in the progression of the disease.  
The majority of cervical cancers contain one or many HPV genome copies, integrated more or 
less randomly into the host cell genome in a monoclonal fashion, with the viral integration site 
frequently lying within the regulatory E1 or E2 genes; this event often leads to the disruption of E2 
and adjacent ORFs (E4, E5, L2), and as a consequence to the loss of expression of full-length E1, 
E2, E4, E5 and late genes (Figure 4). The key event is the loss of E2, which is a virally-encoded 
transcription factor that normally regulates E6/E7 abundance by binding to and silencing the early 
promoter within the LCR as part of a viral regulatory mechanism.  
It is thought that integration occurs in HSIL, and that once this occurs, the already deregulated 
expression of E6 and E7 can increase still further or else be maintained at a constitutive level. 
Moreover E6 and E7 transcripts expressed from integrated copies show increased stability, and this 
was attributed to the longer half-life of transcripts derived from integrated HPV DNA, mediated by 
3’-cellular sequences of the fusion transcripts. Furthermore integration imparts a selective growth 
advantage over cells that harbor only episomal copies of viral DNA. Usually only a segment of the 
viral genome is integrated containing the LCR and truncated parts of the early and late region 
(Figure 4); multiple tandem repeats of such viral DNA fragments - from a single to several hundred 
copies – are often found integrated at random locations in the cellular genome. Upon integration the 
host cells contain an insignificant amount of viral DNA and proteins other than E6 and E7; the E5 
protein might be a weak cofactor in the development of malignancy, mostly in early stages by 
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driving cellular proliferation cooperating with E6 and E7. This is evident in high-risk α-HPV-
positive cervical cancer-derived cell lines, where viral DNA is found to be randomly integrated in 
the host genome leading to the disruption of several viral ORFs and the preservation of E6 and E7, 
which are the only actively transcribed genes. 
Another significant consequence of the integration is the deregulated expression of E6/E7, which 
leads to persistent stimulation of S-phase entry, and the loss of the cellular p53 tumor suppressor 
protein. Thus promoting the emergence of a clonal population of cells with a growth advantage and 
an increased propensity for transformation and malignant progression; this tumorigenic pathway 
requires episome loss, and if viral episomes persist, E2 expression continues to block transcription 
of integrated E6/E7. Noteworthy, the key kinases implicated in sensing and repairing DNA damage, 
ATM – induced in response to double-stranded DNA breaks - and ATR – induced on the 
appearance of single-stranded DNA breaks – whose pathways also involve p53 in downstream 
signaling, which leads to the amplification of integrated HPV sequences and the flanking cellular 
sequences. This combination of events predisposes to the accumulation of secondary genetic 
changes in the host cell genome, and compromises the ability of the cell to effectively repair 
damaged DNA; the consequence is the induction of a condition of genomic and genetic instability 
which further favors progression towards malignancy.  
Experimental models have shown that sustained E6/E7 expression is necessary for the 
maintenance of the transformed phenotype; however, this condition is necessary but not sufficient 
for malignant progression. The accumulation of alterations in the host cell genome, particularly in 
genes controlling the cell cycle, is an important and necessary event in the development of cervical 
cancer, and can appear over time in women who carry persistent active infections. Such mutations 
can occur by chance, or can arise as a result of environmental events. Tobacco metabolites, which 
are present in the cervical secretions of women who smoke, are thought to act as co-factors in the 
development of cervical cancer. Multiparity and the long-term use of oral contraceptives are also 
associated with increased risk, as is the presence of additional genital infections such as Chlamydia; 
hormonal contraception is associated with increased risk due to the effects of estrogens and 
progesterone, which stimulate transcription and cell proliferation inducing also E6/E7 over-
expression.  
Cervical cancer can arise from cells containing exclusively episomes, and for HPV 16, around 
30% of cervical cancers develop in this way; around 70% of HPV16-associated cervical cancers 
contain integrated HPV16 sequences, while for HPV18, the viral genome is almost exclusively 
integrated. Predominantly “episomal” tumors appear characterized by a more favorable natural 
history than “integrated” tumors, correlating with a stronger immune response to L1/L2 coat 
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proteins in the former group. In both cases, however, it is the long-term expression, and in 
particular, the deregulated over-expression of E6 and E7 and the accumulation of genetic errors, 
which are ultimately important in the progression from CIN3 to cervical cancer (Connolly et al. 
2014; Crosbie et al. 2013; Doorbar 2007; Doorbar et al. 2012; Moody and Laimins 2010; 
Tommasino 2014; Wentzensen, Vinokurova, and Doeberitz 2004). 
 
 
Figure 4. Low grade squamous intraepithelial lesions (CIN1) support productive viral replication. 
Progression of untreated lesions to high-grade squamous intraepithelial neoplasia (CIN2/3) and invasive 
cervical cancer is associated with abortive infection and random integration of the viral genome into host 
chromosomes, often characterized by the loss or disruption of E2 and its adjacent ORFs and the preservation 
of the E6 and E7 oncogenes with subsequent deregulation of their expression (Crosbie et al. 2013). 
 
 
Cervical high-risk α-HPV infection: possible outcome  
High-risk α-HPV infection of the uterine cervix can have a number of different outcomes. 
Following infection, expression from the viral genome can sometimes be suppressed (e.g. by 
genome methylation), leading to a silent infection in which the viral episomes are retained in the 
basal epithelial layer without a preceding productive stage and overt disease; such unapparent 
infections can be resolved or persistently remain as sites of viral latency. Infection may alternatively 
establish an ordered pattern of viral gene expression leading to virus synthesis and release from the 
upper epithelial layers, with the formation of a productive CIN1 lesion that in most cases regresses 
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upon clearance of the virus by the host immune system and only in a subgroup of cases evolves to 
HSIL and consequent cervical cancer. 
Despite the high incidence of high-risk α-HPV infection of the genital tract among sexually 
active individuals, the majority (80-90%) of new infections at any age are cleared without any 
apparent clinical disease. The regression is the result of an immune response mainly mediated by T-
cells and NK, and the infection do not persist long enough for deregulated gene expression and the 
accumulation of secondary genetic errors to occur. The majority of those who develop productive 
CIN1 lesions eventually mount an effective cell-mediated immune response and the lesions 
spontaneously regress; infections are usually resolved in a short term period (12-18 months), with 
re-infection by the same HPV type being uncommon. 
The failure to develop effective cell-mediated immunity to clear or control infection results in 
persistent infection and in an increased probability of progression to HSIL and invasive carcinoma. 
It has been suggested that HPV 16 and 18 may be more persistent than other high-risk α-HPV types, 
explaining the great proportion of cervical cancers caused by these two types compared to the 
others and therefore their higher oncogenic potential.  
Effective evasion of the innate immune recognition seems to be the hallmark of high-risk α-HPV 
infections. HPV globally down-regulates the innate immune signaling pathways in the infected cells 
through multiple ways: interference with attractive chemokines; down-regulation of the expression 
and signaling of pro-inflammatory cytokines; down-regulation of the antiviral IFN response; up-
regulation of anti-inflammatory cytokines that prevent migration of immune cells to the sites of 
infection; attraction and retention of suppressive regulatory T cells; down-regulation of TLR 
expression; reduction in the activation of antigen-presenting cells and in peptide presentation 
abilities. Many of the mechanisms of immune evasion by high-risk α-HPVs have been established 
and seem to be driven by specific functions of E5, E6 and E7 oncoproteins. 
The fact that HPV exhibit an exclusively intraepithelial life cycle avoiding cell lysis and necrosis or 
viraemic phase that would trigger inflammatory responses, and that viral proteins are massively 
expressed only in the upper epithelial layers, well away from circulating immune cells, may further 
restrict detection by the host immune system. The viral early proteins, which are expressed also in 
the lower epithelial layers, are thought to be produced at low levels below those required to 
effectively trigger an immune response. In contrast to lytic viruses which are rapidly detected by the 
host immune system causing host cell destruction at the terminal stage of infection, antibodies 
directed against HPV capsid proteins arise as late as 6-12 months following the infection.  
When lesion regression does occur, viral gene expression is shut off in the presence of the 
infiltrating lymphocytes (possibly as a result of cytokine signaling), but the viral genomes may not 
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be effectively cleared from the basal layer being still persistently present in a subset of epithelial 
stem cells in a latency status. The lesion is cleared by the replacement of actively infected cells with 
“apparently normal cells” as the basal cells continue to divide; these “apparently normal cells” may 
still contain viral genomes with very low-level expression of viral gene products and without 
completion of the life cycle – only some occasional bursts of virus production that may explain the 
frequent detection of viral DNA in the absence of disease. Latent infection is thought to require E1 
and E2 to allow basal cell replication of viral episomes, but is not thought to depend on the 
expression of E6 and E7.  
It has been suggested that the life cycle may become reactivated subsequently following changes in 
hormone levels or in presence of immunosuppression; individuals with immune function defects, 
such as OTRs or HIV patients, are affected by pathological conditions associated with reduced T-
cell function, leading to an impairment of antiviral immune surveillance that may be responsible for 
the rise in viral genome copy number at the regressed sites. Studies on immunocompromised 
patients, such as OTRs or HIV-positive subjects, have shown an increased prevalence of detectable 
single or multiple high-risk HPV infections and associated lesions, compared with healthy people. 
Accordingly, in such individuals the incidence of HPV-related cervical cancers and other genital 
cancers is significantly higher compared with the general population.  
For cancer to develop, it’s well known that the virus has to evade immune detection over a 
prolonged period to lead the accumulation of genomic and genetic abnormalities. High-risk α-HPV 
chronic infections characterized by long persistence in the slow-cycling epithelial stem cells in the 
absence of apparent disease is a condition sine qua non for the development of HPV-associated 
malignancy; although it is clear that high-risk E6 and E7 target cellular pathways related to innate 
and adaptive immunity, host and environmental factors significantly contribute to the chronicity of 
high-risk α-HPV infection. Cancer progression typically occurs over years of decades in patients 
that do not effectively resolve their initial infection as their immune system fails to clear the 
infected basal stem cells and the virus; this long time is required for the acquisition of secondary 
genetic changes.  
All these issues suggest that even if high-risk α-HPV infection is decisive for the process, on its 
own it is not sufficient to induce the development of a malignant tumor; a number of other factors 
are decisive for the neoplastic transformation of the epithelial cells of the uterine cervix, including 
age, health and habits of the infected individual, the duration of the infection and environmental 
factors (Cid Arregui et al. 2012; Ciesielska et al. 2012; Doorbar 2007; Doorbar et al. 2012; Moody 
and Laimins 2010; Tommasino 2014). 
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The high-risk α-HPV oncoproteins 
The development of cervical cancers involves a coordinated targeting of multiple pathways by 
high-risk α-HPV oncoproteins, with each pathway having a distinct role in malignant progression. 
These viral proteins disrupt or usurp multiple cellular signalling pathways to maintain infected cells 
in a proliferative state to facilitate viral replication. One important consequence of this, however, is 
the accumulation of mutations in cellular genes and increased genomic instability, which results in 
full transformation. In addition, high-risk oncoproteins also enable immune escape in order to allow 
viral persistence in the host. The primary viral factors responsible for altering these pathways and 
mediating progression to malignancy are the E5, E6 and E7 proteins, with E6 and E7 playing a 
central role in these processes and acting in a cooperative manner (Moody and Laimins 2010). 
 
It is becoming clear that both mucosal E6 and E7 interfere with a broad spectrum of cellular 
targets, and that the identity of these substrates differs between HPV types of the same high-risk 
clade, as well as between the high-risk and low-risk groupings themselves, conferring oncogenic 
properties to various extents depending on the specific mucosal α-HPV species and types; this is 
due to different biochemical properties of high-risk and low-risk E6 and E7, with aminoacid 
substitutions differentially affecting their activity. The high-risk and low-risk α-HPVs also have 
significant differences in promoter positioning and regulation, as well as in patterns of mRNA 
splicing. These differences affect expression from the E6 and E7 genes. It is thought that different 
patterns of viral gene expression, as well as different protein functions, play a major role in 
determining disease phenotype following infection (Doorbar et al. 2012). 
 
The mucosal E6 and E7 proteins are typically expressed together in infected cells, from a 
common early promoter. There is a value, however, in dissecting their specific functions by 
expressing them individually.  
The expression of high-risk E7 proteins by themselves can immortalize cultured human 
keratinocytes – which are known to have a short replicative lifespan in vitro - at a low frequency but 
high-risk E6 has no such activity, since it can only extend the lifespan of keratinocytes. The 
combination of high-risk E6 and E7, however, is highly efficient at immortalizing most types of 
primary cells in culture. Low-risk E6 and E7, on the contrary, do not readily extend the lifespan of 
keratinocytes, with occasional subpopulation of cells emerging that are immortal. The growth of 
keratinocytes expressing both high-risk E6 and E7 in organotypic raft cultures, which faithfully 
duplicate epithelial stratification and differentiation, results in cellular changes identical to those 
observed in HSIL in vivo, further demonstrating the importance of these factors in HPV 
pathogenesis.  
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In addition, transgenic mice that express high-risk E6 and E7 in basal epithelial cells exhibit 
epidermal hyperplasia and develop squamous carcinomas on low-dose oestrogen treatment or 
chemical carcinogens. In these mouse models, the phenotype correlated with high-grade cervical 
dysplasia and invasive cervical malignancies is primarily due to E7 expression. On the contrary, 
high-risk E6 alone has modest transforming functions when expressed as a transgene from a 
keratin-specific promoter in the epithelium of mice. The co-expression of high-risk E6 and E7 
results in larger and more extensive cervical cancers, highlighting their cooperative activity in 
promoting tumorigenesis (Moody and Laimins 2010; Vande Pol and Klingelhutz 2013; Tommasino 
2014). 
 
The high-risk and low-risk E7 proteins exhibit differential ability to associate with members of 
the Retinoblastoma (Rb) protein (pRb) family. The high-risk E7 proteins are able to bind and target 
for ubiquitin-dependent degradation - through interaction with ubiquitin-ligases such as Cul2 and 
UBR4 - both p105 and p107, which control cell cycle entry in the basal epithelial layer, as well as 
p130, which is involved in cell cycle re-entry in the mid-upper epithelial layers. The low-risk E7 
proteins generally appear to have a lower affinity for p105 and p107 than high-risk E7, but can 
associate with and degrade p130 in order to create a replication-competent environment in the mid-
epithelial layers that is suitable for genome amplification.  
An unfortunate characteristic of the high-risk E7 proteins is their ability to stimulate host 
genome instability, particularly through deregulation of the centrosome cycle in the proliferating 
basal epithelial cells. E7 induce multiple rounds of centrosome synthesis in a single S-phase 
through the formation of multiple immature centrioles from a single maternal centriole. This may be 
due to the binding of E7 to γ-tubulin, a centrosome regulator. This interaction seems to be 
independent of the Rb binding ad result in removal of γ-tubulin from the mitotic spindle, which may 
lead to abnormal centrosome synthesis. An abnormal centrosome number can bring to an 
accumulation of mitotic abnormalities such as chromosomal missegregation. Further the 
development of aneuploidy that may increase the chance of genetic errors during each round of host 
cell division. Indeed, most HPV-associated malignancies have numerous chromosomal imbalances, 
including aneuploidy and chromosomal rearrangements. 
High-risk E7 in cooperation with E6 can also stimulate genomic instability through the induction of 
DNA damage and the activation of the ATM-ATR pathway; such activation of the cellular DNA 
repair machinery is harnessed for viral replication in differentiated keratinocytes and can lead to an 
increase in the frequency of foreign DNA integration into the host genome. An important aspect is 
also that E7 induce the proteolytic degradation of claspin, a key regulator of the ATR DNA damage 
signaling pathway that is activated in response to replication stress; the accelerated degradation of 
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claspin by high-risk E7 in G2-M checkpoint may “trick” host cells into initiating checkpoint 
recovery, allowing aberrant mitotic entry in the presence of DNA damage and potentially leading to 
genomic instability through defective DNA repair.  
In addition to RB destabilization, E7 contributes to immortalization through interaction with key 
proteins that control cell cycle progression.  
The high-risk E7 proteins are able to bind the CDK inhibitors p21 and p27, which are important 
regulators of growth arrest during epithelial differentiation whose major target is CDK2, important 
for G1-S transition and cell cycle progression. As a consequence, the p21 and p27 repressor effects 
on the cell cycle are neutralized and CDK2 activity remains high in E7-expressing cells despite high 
levels of p21. E7-mediated p21 inactivation is one of the ways through which high-risk α-HPVs 
inhibit p53 signaling in the infected cells. Low-risk E7 proteins can also bind p21 but with a greatly 
reduced efficiency and a decreased ability to abrogate its inhibitory effects.  
In addition, high-risk and low-risk E7 can bind indirectly to cyclin-CDK2 complexes through pRB, 
p107 or p130, as well as directly to CDK2 and/or cyclin subunits, allowing sustained CDK2 
activity. High-risk E7 has further been shown to increase the levels of the CDC25A phosphatase, 
which can induce tyrosine dephosphorylation of CDK2, promoting its activation.  
All these E7-dependent mechanisms of CDK2 abnormal activation allow G1-S checkpoint to be 
bypassed, as it occurs upon E7-mediated abrogation of Rb protein activity.  
The high-risk E7 proteins promote premature S phase entry and DNA synthesis with the 
disruption of the Rb-E2F complex resulting in the constitutive expression of E2F responsive genes. 
E7 interact also with histone-deacetylases, a class of enzymes that act as co-repressors of gene 
transcription and directly bind and down-regulate the E2F promoter, and with E2F transcriptional 
repressors; as a result, the suppressive activity of these factors is abrogated and the transcription of 
genes involved in G0/G1-S transition is promoted, further stimulating host cell proliferation. 
Another mechanism by which the high-risk E7 proteins contribute to host cell transformation is 
the ability to induce histone code modifications (e.g. demethylation), leading to epigenetic 
reprogramming, as demonstrated by the aberrant expression of homeobox genes – which control 
cell fate and identity – in host cells. 
The high-risk E7 proteins have also been demostrated to induce autophagy in primary human 
epithelial cells under conditions of metabolic stress, and to promote the Warburg effect, a 
reprogramming of the cellular metabolism to aerobic fermentation and a general hallmark of human 
tumor cells. 
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Finally, high-risk proteins E7 interact with components of the interferon (IFN) response, 
contributing to escape from immune surveillance and the establishment of a persistent infection. 
They bind to and inactivate IRF1 and IRF9, inhibiting their ability to stimulate IFN transcription 
and therefore blocking the IFN response that is normally activated following viral infections; high-
risk E7 in cooperation with E6 down-regulate STAT1, which is a key transcription factor that 
regulates the IFN response and its repression may be crucial for the inhibition of this activity. High-
risk E7 can also repress the expression of the adhesion molecule E-cadherin, which is thought to 
underlie the lower abundance of antigen-presenting cells in the vicinity of the lesions; this function 
may increase the invasiveness of the infected cells as well. Furthermore, high-risk E7 reduce the 
expression of genes involved in peptide presentation and activation of the antigen-presenting cells 
(Ciesielska et al. 2012; Crosbie et al. 2013; Doorbar et al. 2012; McLaughlin-Drubin, Meyers, and 
Munger 2012; Moody and Laimins 2010; Roman and Munger 2013). 
 
Another characteristic of both high-risk and low-risk E6 proteins bind to and inactivate p53, but 
only high-risk E6 stimulate its proteolytic degradation. High-risk E6 recruit the cellular ubiquitin-
ligase E6AP and mediate the ubiquitination and proteasomal degradation of p53 through the 
formation of a strong tripartite complex E6-E6AP-p53. Low-risk E6 can also associate with E6AP 
but surprisingly this does not result in p53 degradation, suggesting that other cellular factors are 
targets for the low-risk E6-E6AP complex. The transcriptional activity of p53 could be inhibited 
through direct binding by low-risk E6, and this may be the predominant mechanism by which low-
risk HPVs inhibit the growth-suppressive effects of p53.  
In addition, high-risk and low-risk E6 interfere with p53 function by suppressing the activity of 
different histone-acetyltransferases (e.g. CBP/p300 and Ada3), blocking the ability of these factors 
to acetylate p53 and therefore increase its stability; the result is a destabilization of p53 transcription 
complexes and their conversion from co-activators to repressors.  
In a persistent infection, all these p53-targeting high-risk E6 functions compromise the 
effectiveness of the p53-mediated cellular DNA damage response in cells that are driven into S-
phase by E7 over years or decades, and allow the accumulation of secondary mutations to go 
unchecked, eventually leading to cancer. 
The high-risk E6 proteins exhibit a conserved PDZ-domain-binding motif located at the C-
terminus; this motif allows interaction with several PDZ targets, in particular proteins of the 
MAGUK family localized in the cell membrane, which are generally believed to be associated with 
the cellular membrane and affect such processes as cell polarity, maintaining cell-to-cell 
interactions, and mediating signals from membrane. E6/MAGUK interaction, leads to degradation 
of the cellular protein; the consequence is the abrogation of the functions of all these proteins: loss 
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of cell-cell contacts upon degradation of proteins forming intercellular junctions, leading to loss of 
cell polarity and anchorage-independent cell growth. All these conditions are important in the 
development of malignancies. 
The high-risk E6 proteins balance the E7-induced metabolic stress by activating mTORC1, a 
complex controlling protein synthesis and functioning as a nutrient, energy and redox sensor; the 
result is a state of blissful ignorance of cellular nutrient supply, and a stimulation of protein 
synthesis facilitating viral replication in terminally differentiating cells even with low nutrient 
supply. Increased mTORC1 activity has been detected in HPV-associated pre-malignant lesions and 
cancers. 
Another characteristic of the high-risk E6 proteins is their capacity to up-regulate telomerase 
activity and maintain telomere integrity during repeated cell divisions. In somatic cells every 
consecutive division of a cell results in abbreviated telomeres. Telomere length reflects the age of 
the cells. Elevated telomerase activity, which adds additional telomere sequences, has been 
documented in human neoplastic cells, and it has been suggested that this may be of significance in 
the development of tumors. High-risk E6 activate the catalytic subunit of telomerase (hTERT) 
through E6AP by interacting with myc and modulating the activity of repressors (USF, NFX-91 
which is targeted for degradation) and activators (myc-max, SP1, and histone-acetyltransferases) 
that bind to and induce the hTERT promoter. E6-mediated hTERT activation stimulates the addition 
of hexamer repeats to the telomeric ends of chromosomes, allowing maintenance of their length and 
indefinite proliferation, which is expected to inhibit cell senescence and extend the lifespan of cells 
harboring viral genomes; such immortalizing effects may predispose to persistent infection. 
It has been reported that high-risk E6 proteins can induce down-regulation of specific genes that 
are involved in keratinocyte differentiation; this might delay host cell differentiation until enough 
genomes have been replicated for subsequent production of infectious virions. Through unknown 
mechanisms probably involving interactions with transcription factors and signaling proteins, high-
risk E6 also affects the expression of miRNAs involved in targeting cell cycle control genes and in 
the regulation of cell migration. This activity of modulation of the expression of specific cellular 
genes may contribute to tumor undifferentiation, growth and invasion. 
The high-risk E6 and E7 proteins also interfere with the effects of various growth inhibitory 
cytokines that are induced following infection and can activate apoptotic pathway. In response to 
viral entry, cells produce inflammatory mediators such as TNFα, which is a potent inhibitor of 
keratinocyte proliferation. Inflammatory cytokines can activate the extrinsic apoptotic pathway 
through transmembrane cell surface death receptors of the TNF receptor family, such as TNFR1, 
FAS and TRAIL receptors. High-risk E6 block TNFα-induced apoptosis by directly binding to 
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TNFR1, which inhibits the formation of the death-inducing signaling complex and consequent 
transduction of apoptotic signals. It can also interact with the adaptor protein FADD and caspase 8 
to block cell death in response to FAS and TRAIL.  
High-risk E6 can also interfere with induction of mitochondrial apoptotic pathways through 
interactions with the pro-apoptotic Bcl2 members Bak and Bax, inducing their ubiquitin-dependent 
proteasomal degradation via E6AP; in addition, they can induce up-regulation of inhibitors of 
apoptosis such as IAP2 and survivin, which can occur through E6-mediated activation of NF-κB. It 
is unclear if low-risk E6 function in a similar manner; they have been reported to be able to induce 
Bak proteolytic degradation. 
Anoikis is another apoptotic pathway targeted by high-risk E6, which is an essential and conserved 
mechanism found in multicellular organisms that functions to prevent the abnormal detachment of 
cells in the host. High-risk E6 have been reported to bind to paxillin, which is a key downstream 
mediator in the induction of this process. These interactions promote resistance to anoikis and allow 
HPV-immortalized cells to proliferate, establishing anchorage-independent cell growth, 
fundamental characteristic in tumor progression and invasion. 
Like high-risk E7, E6 can interfere with the IFN antiviral response and facilitate viral escape 
from immune surveillance. 
Both the high-risk and the low-risk E6 proteins repress the transcription of many IFN-inducible 
genes, including Stat1. High-risk E6 directly interact with components of the IFN response, such as 
IRF3, resulting in inhibition of IFN transcription.  
In addition, high-risk E6 overcome the growth-suppressive effects of IFN through the formation of 
a tripartite complex with p53 and CBP/p300 (which is the downstream mediator of the p53-
dependent IFN antiproliferative response). 
 This interaction prevents the acetylation of p53 and blocks the activation of p53-target genes, 
allowing continued viral replication in the presence of IFN. Importantly, the binding of E6 to 
CBP/p300 may further facilitate viral escape from immune surveillance and establish long-term 
persistence; p300/CBP is a co-activator of the NF-κB transcription factor, which controls among 
other things the promoters of certain interleukins which are down-regulated as a consequence of E6 
action.  
Like high-risk E7, high-risk E6 can also contribute to immune escape by reducing the ability of 
epithelial cells and antigen-presenting cells to present viral antigens and to activate, affecting the 
expression of key proteins in this process; in addition, they reduce E-cadherin expression with 
similar effects to its E7-mediated repression. Finally, another mechanism by which both high-risk 
and low-risk E6 can locally down-regulate host immune responses is the binding and inactivation of 
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Tyk2 kinase of the Jak-Stat pathway, which is critical in cytokine signaling (Ciesielska et al. 2012; 
Crosbie et al. 2013; Vande Pol and Klingelhutz 2013; Tommasino 2014; Doorbar 2007; Doorbar et 
al. 2012; Moody and Laimins 2010; McLaughlin-Drubin, Meyers, and Munger 2012). 
 
Although E6 and E7 provide the primary transforming activities of high-risk α-HPVs, E5 can 
augment their function and contribute to tumor progression. In general E5 proteins alone have 
weaker transforming activity compared to E6 and E7, in contrast some few genotypes show strong 
transformation activity. Cellular and mouse models have shown that the high level expression of 
high-risk E5 induce spontaneous tumours formation; suggesting that in some cases they seems to be 
able to act as oncoproteins. They are thought to enhance the transforming activity of E6 and E7 by 
promoting host cell hyperproliferation through their mitogenic and anti-apoptotic actions in early 
stages of the tumorigenic processes, before the occurrence of viral DNA integration in cervical 
HSIL. 
Dimeric complexes of E5 protein are able to trigger cell fusion, yielding binucleate polypolid 
cells via endoreduplication (koilocytes) which are typical of α-HPV-associated lesions. Another 
reported high-risk E5 activity is the reduction in E-cadherin expression, which is a function also 
mediated by E6 and E7; in addition, high-risk E5 can inhibit the host MHC class II complexes, thus 
compromising the display of viral peptides by the infected epithelial cells and contributing to viral 
immune escape (Moody and Laimins 2010; Connolly et al. 2014).  
  
 
Papillomavirus vaccine and cervical screening 
Understanding of the ubiquitous role of high-risk α-HPV infection in all CIN lesions and cervical 
cancer combined with an understanding of HPV natural history has led to the development of the 
first prophylactic cancer vaccines. These vaccines contain L1 self-assembling recombinant non-
infectious virus-like particles, which closely resemble the structure of native virions and are highly 
immunogenic leading to strong neutralizing specific antibody responses against HPV infection. 
These antibodies are thought to block the HPV virions before they gain access to the proliferating 
basal cell layer of the epithelial surface.  
Two vaccines are available - the quadrivalent vaccine (Gardasil, Merck), which contains virus-
like particles to HPV 6, 11, 16 and 18, and the bivalent vaccine (Cervarix, GlaxoSmithKline), 
which contains virus-like particles to HPV 16 and 18. Both vaccines protect against precancerous 
lesions associated with the high-risk types HPV 16 and 18. The quadrivalent one is also able to 
confer protection against benign mucosal lesions associated with the low-risk types HPV 6 and 11. 
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Efficacy is close to 100% according to different trials. These vaccines seem also to provide a sort of 
cross-protection to non-vaccine HPV types, associated with immune responses against HPV types 
that are phylogenetically related to HPV 16 and 18 respectively (e.g. HPV 31).  
The two HPV vaccines were not designed as therapeutic vaccines and have little, if any, 
prophylactic effectiveness in people that have been previously exposed to the vaccine HPV types; 
although they block initial infection with the vaccine HPV types, they do not induce regression of 
ongoing lesions and cannot prevent the progression to cancer in already infected individuals. 
To manage a wider range of on-request vaccinations, many countries have included a catch-up 
range for vaccination in HPV-naive individuals, which overlaps with the typical age of onset of 
sexual activity.Although the primary focus of HPV vaccination programs has been on women and 
girls - who bear the greatest burden of HPV-associated cancers - recent clinical trial data showing 
efficacy of vaccination in men and the potential for herd immunity have led to vaccination of 
adolescent boys to be recommended in some developed regions; indeed, the HPV vaccines have 
recently been approved for use in men to prevent the development of HPV-associated penile 
cancers.  
However, the comprehensive preventive cervical screening programs remain the only strategy 
that has avoided a corresponding epidemic of cervical cancer. Thus, it is important for women to 
continue to undergo cervical screening, as infections with other high-risk α-HPV types not targeted 
by the vaccines can still occur. Cervical screening can be performed either by traditional cytological 
analysis – Papanicolau smears (PAP smears), allowing to detect cervical disease and predict its 
severity from the examination of exfoliated cells scraped from the epithelial surface – or by HPV 
DNA/RNA testing. Pap smear screening programs can identify most premalignant lesions. 
Appropriate follow-up of women with these abnormalities, together with appropriate treatment, can 
thereby prevent the development of most cases of cervical cancer. In countries with screening 
programs, however, the incidence of adenocarcinoma and adenosquamous cell carcinoma has been 
increasing, suggesting that Pap smear screening may be less effective in identifying the precursors 
to these tumor types. DNA/RNA testing detects HPV infection that is far more common than 
prevalent disease but is also a biomarker of increased future risk. Widespread HPV vaccination and 
cervical screening are absolutely required to reach a significant decrease in incidence of HPV-
induced cervical disease, especially in developing countries where cervical cancer burden is still 
considerable. Since high-risk α-HPVs cause tumors years of decades after the initial infection, the 
currently available prophylactic vaccines will not have a measurable impact on HPV-associated 
cancer rates for two or three decades (Crosbie et al. 2013; McLaughlin-Drubin, Meyers, and 
Munger 2012; Moody and Laimins 2010; Knipe and Howley 2007). 
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β-HPVs and skin carcinogenesis 
While the causative relationship between HPV infection and genital SCCs is well established, 
the role of HPV in the development of cutaneous malignancy is, as yet, unclear. However, there is 
increasing evidence showing the involvement of cutaneous β-HPV in the development of Non 
Melanoma Skin Cancer (NMSC). To demonstrate that a pathogen causes cancer, convincing 
epidemiologic evidence of association and a plausible biological mechanism for oncogenesis are 
fundamental; while this has been achieved for high-risk α-HPVs and cervical cancer, such 
requirements have not yet been satisfied for β-HPVs and NMSC, as there is great lack of 
consistency among epidemiological studies and no molecular role for these viruses in cutaneous 
tumorigenesis has been certainly proven so far. 
NMSC is the most common cancer type among Caucasians, where it accounts for around 30% of 
all malignancies and its rates are increasing by 4–8% yearly. Although the majority of NMSC cases 
can be treated surgically and do not usually exhibit high aggressiveness, these cancers are 
associated with high morbidity and represent a significant burden on the healthcare system. 
Immunosuppression and UV exposure are the main risk factors for NMSC – these tumors mostly 
arise in sun-exposed skin sites. 
The major histological types of NMSC are basal cell carcinoma (BCC) and cutaneous squamous 
cell carcinoma (cuSCC), associated with different underlying mutational patterns. BCC is more 
common in fair-skinned individuals and originates from transformation of basal epidermal cells. 
cuSCC, which is more aggressive than BCC, is more common among darker skin population and 
arises from transformation of squamous epidermal cells; it is usually preceded by precancerous 
lesions, namely actinic keratosis (AK), with high potential to undergo malignant progression; other 
forms of skin tumors that are histologically related to cuSCC are keratoacanthoma – a low-grade 
cuSCC subtype originating from the hair follicles, able to regress spontaneously and representing a 
midpoint between a benign wart and invasive cuSCC – and Bowen’s disease – an early stage in situ 
intraepidermal form of cuSCC (Akgül, Cooke, and Storey 2006; Aldabagh et al. 2013; Ingo Nindl, 
Gottschling, and Stockfleth 2007; Knipe and Howley 2007; Pfister 2003; E-m de Villiers 1998). 
 
Has been shown that cutaneous β-HPVs are ubiquitously widespread and cause asymptomatic 
latent infections without apparent disease in the general healthy population. Thus the 
epidemiological demonstration of a possible causal link between infection and NMSC development 
is complicated; it is thought that everybody is positive for multiple β-HPV types. With increasing 
age, the number of infecting β-HPV types seem to rise; β-HPV persistence with the same types is 
common, and family members often share the same types (“β-HPV signature”); more than half of 
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the HPV types detected in the specimens from the babies were also isolated from the respective 
parents, even although only one sample per parent was obtained and analyzed. 
 Different studies using different sampling techniques have shown that the most commonly detected 
β-HPV types are HPV 5, 8 and 23; different ethnicities may harbor different β-HPV types, with 
HPV5 being the most prevalent type and the only type common to all countries studied. 
Several studies have reported the ubiquitously presence of these viruses on the body surface, 
with greater carriage in sun-exposed sites (e.g. forehead) than is sun-protected skin when its 
presence was monitored in plucked hairs and skin swabs; they appear to establish a reservoir of 
infection in the follicular stem cells of hair bulbs, which are thought to be an immune privileged site 
protecting them from immune clearance and therefore enabling the persistence of multiple β-HPV 
types. However, viral DNA in normal skin is usually detected at very low genome copy numbers, 
rarely being higher than one genome copy per cell. 
β-HPV infection seems to be acquired during or shortly after birth; the presence of the viruses on 
the skin surface of the mother and other people in close contact with the newborn is the most likely 
source of infection. Transmission of β-HPV probably takes place via direct contact with infected 
skin or derivate thereof such as scales and dandruff; the likelihood of a prenatal vertical 
transmission from mother to fetus has also been proposed. Transmission in later stages of postnatal 
life is thought to be limited; this may be due to the fact that in the first postpartum days, the thinner 
horny layer facilitates access to the basal layer, or to the fact that after the sites available to 
infection have been occupied, the settlement of other β-HPV types is more difficult because of the 
occurrence of a cross-reactive antiviral response following initial infection. In immunocopetent 
individuals, this early infection seems to persist in a latency status and without clinical 
manifestations (Akgül, Cooke, and Storey 2006; Aldabagh et al. 2013; Bouwes Bavinck, 
Plasmeijer, and Feltkamp 2008; Harwood and Proby 2002; Feltkamp et al. 2008; Pfister 2003).  
 
 
Epidermodysplasia verruciformis 
Epidermodysplasia verruciformis (EV), which is considered to be a primary immunodeficiency 
(PID), is the first evidence for the involvement of HPV infection in the development of skin cancer. 
To date, is the only setting where the association between β-HPV infection and skin carcinogenesis 
has been ascertained.  
It is a rare autosomal recessive condition, in which selective depletion of specific T-cell clones - 
although the immunophenotype might be normal in some patients - is associated with an abnormal 
susceptibility to persistent infection restricted to a subset of about 20 β-HPV types. Multiple 
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infections are more frequent rather than the presence of one infecting type. These patients usually 
develop warts in childhood, which become widespread, do not tend to regress, and, in some 
instances, may progress to squamous cell cancers. Two predominant types of lesions are seen, 
which can occur in the same patient. Some lesions have the appearance of flat warts, whereas others 
are flat, scaly, red-brown macules. The plane warts are usually associated with the cutaneous α-
HPV types HPV 3 and 10 and occurring mainly on the trunk, neck and extremities, those persist 
lifelong. The flat warts are caused by the same HPV type that induces flat warts in the general 
population, usually α-HPV 3 or 10. The scaly lesions are associated with EV-specific HPV types, 
most frequently β-HPV 5 and 8; often with more than one β-HPV type being detected, and contain 
high β-HPV episome copy numbers per cell – indicating a high level of viral replication – and 
abundant E6 and E7 transcripts – indicating viral gene expression in the lesional tissue.  
In the fourth decade of life, around 30-60% of EV patients develop malignant tumors in sun-
exposed sites, which are usually low grade in situ carcinomas with some features in common with 
Bowen’s disease, but others are more aggressive cuSCC. HPV 5 and 8 account for 90% of the 
tumors with HPV 14, 17, 20 and 47 accounting for the remainder. Extrachromosomial β-HPV DNA 
can reach 100-300 genome copies per cell, even though in a limited number of tumor cells. Unlike 
cancers caused by high-risk α-HPVs, β-HPV-induced EV skin tumors are associated with 
productive infections. The high level of viral replication and subsequent active oncogene expression 
underlies skin carcinogenesis in these patients.  
Most of EV patient (approximately 75%) present homozygous truncating mutations in EVER1 or 
EVER2 genes; these two genes encode transmembrane proteins expressed in a variety of cells 
types, including hemopoietich cells. These protein form a complex localizing to the endoplasmic 
reticulum, where they seem to control intracellular zinc homeostasis and in particular to decrease 
the nuclear zinc concentration, acting as negative regulator of the activity of zinc-regulated 
transcription factors necessary for viral gene expression (e.g. AP1); thus, the EVER proteins may 
act as restriction factors for β-HPV gene expression and replication in keratinocytes, even though 
the exact underlying mechanisms are still unclear. EVER mutations disrupt zinc transport between 
cell compartments; it is thought that this leads to up-regulation of transcription factors that can 
induce β-HPV transcription and stimulate keratinocyte proliferation, which in turn further amplifies 
β-HPV oncoprotein expression. Other HPV species may counteract EVER protein function through 
different mechanisms in order to facilitate viral gene expression; HPV16 E5 has been reported to be 
able to bind and inhibit the EVER complex. 
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However, in a substantial proportion of patients clinically diagnosed with EV, EVER genes are not 
mutated; suggesting that unknown mutations affecting other genes are involved in the genetic 
background of these patients.  
More recently, mutations in other two genes, the ras homolog gene family member H (RHOH) 
encoding a Rho-GTPase expressed predominantly in hematopoietic cells involved in intracellular 
transduction form T-cell and B-cell receptors, and MST1 encoding a kinase involved in many 
biological processes in various cell types, including apoptosis, negative regulation of cell growth 
and proliferation, and differentiation. These to mutation have been identified in PID patients 
associated with high susceptibility to β-HPV infections exhibiting an EV-like phenotype. Both 
RHOH and MST1 deficiencies lead to T-cells defects, which probably play a role in the 
pathogenesis of chronic active β-HPV infections (Akgül, Cooke, and Storey 2006; S Tuttleton 
Arron et al. 2011; Crequer et al. 2012; Crequer, Troeger, and Patin 2012; Cubie 2013; Leiding and 
Holland 2012; Pfister et al. 2003). 
 
Epidemiological approaches to investigate β-HPV infection and association with NMSC 
The DNA by PCR-based methods and genotyping in skin biopsies, skin swabs or plucked hairs, 
serological analyses for the detection of anti-β-HPV antibodies are the principal approaches that 
have been performed for the epidemiological investigation of β-HPV infection and the analysis of a 
possible involvement of β-HPVs in the pathogenesis of NMSC in non-EV patients. 
Skin biopsy is considered the gold standard in sampling for β-HPV testing. Skin biopsies are the 
most clinically adequate samples for this intention and can yield information about β-HPV in 
epidermal layers deep to the horny layer, which may reveal virus presence in the stem cells of the 
hair follicle or the eccrine ducts. Nonetheless, it is not known whether β-HPV DNA detection 
represents viral particles or superficial or deep infection. Moreover biopsy are minimal invasive but 
requires performer skill and moderate cost, making it an impractical approach for large cohort 
studies.  
Skin swabs are a more convenient sampling method, allowing for quick, noninvasive, painless 
sampling that can be repeated multiple times with little risk. The disadvantage is that it is difficult to 
determine whether a positive sample represents contamination, carriage, or transient or persistent 
infection. Presumably, the presence of the same β-HPV types in multiple samples over a period of 
time would be more likely to be because of persistent infection.  
Plucked hairs represent another tissue specimen that may be tested for β-HPV, being hair follicles a 
reservoir site for β-HPV infection. This sampling method is noninvasive, comport little risk and can 
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be performed multiple times like in the case of skin swabbing; in addition, it should have a lower 
risk of surface contamination than skin swabs.  
Finally, blood samples can be used to identify serum antibodies to specific β-HPV types. Drawing 
blood is simple and quick and can be repeated multiple times; antibody responses are often very 
durable and can serve both as markers of present infection and as a fossil record of infection, even if 
tissue specimens do not ultimately contain viral DNA sequences. Disadvantages of the 
seroepidemiological analysis are: not all hosts mount an antibody response to HPV, seroconversion 
may only appear months afterwards the infection, cross-reactive antibodies between different β-
HPV types may complicate the picture and individual studies of known viral serotypes are required; 
in addition, information gathered is obviously limited to serology. 
The major limitation of all these approaches is that they just aim at the detection of viral DNA or 
host antibody responses without providing any direct evidence for active β-HPV infection. Due to 
the widespread asymptomatic infection in the general population, more biologically relevant 
techniques allowing to detect and monitor viral activity in terms of replication and gene expression 
rather than infection per se – that might be only due to transient or latent carriage or surface 
contamination - should be used to get deeper insight into any possible implication of β-HPVs in the 
pathogenesis of NMSC; indeed, the difference between cases and healthy individuals may not lie 
either in the presence or absence of infection or in the amount of viral DNA, but rather in the extent 
of viral replication and gene expression. In addition, all the epidemiological studies performed to 
date have used multiple sampling and detection methods, small sample sizes (with some exceptions) 
and detection restricted to specific β-HPV types (Aldabagh et al. 2013; Feltkamp et al. 2008; Pfister 
2003; Schiller and Buck 2011). 
 
 
Epidemiological evidence in the general population 
In the first place, the frequency of detection of HPV strictly depends on the HPV detection 
system and the geographic location where the study has been performed. In the general population 
β-HPV seroprevalence has been estimated to be around 30-80% according to different 
seroepidemiological studies; viral DNA prevalence detected in PCR-based analyses is higher, over 
80-85% in most studies with differences depending on the type of samples investigated. 
Numerous studies have examined the presence of β-HPV DNA or anti-β-HPV antibodies in 
sporadic NMSC, premalignant and benign lesions, as well as normal, uninvolved skin in 
immunocompetent individuals. Beside the wide number of studies, the role of β-HPV in the 
development of NMSC is, as yet, unclear. 
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Indication in favor of an association between β-HPV infection and sporadic NMSC: 
- Greater β-HPV DNA carriage, even with multiple infecting types, in cuSCC and AK (to a lesser 
extent also BCC and benign lesions) comparing with healthy skin, furthermore 50% of cuSCC 
are β-HPV DNA-positive  
- According to different studies, β-HPV DNA is more associated with sun exposure in both 
lesions and healthy skin 
- Positive correlation between history of NMSC and higher rate of β-HPV DNA detection in 
normal skin has been demonstrated 
- Some studies have shown β-HPV DNA to be more common and with higher load in precursor 
AK lesions than cuSCC, BCC, benign lesions and normal skin 
- Most seroepidemiological studies have found a positive relationship between antibody response 
to β-HPV (whether against a single or specific type or multiple types) and cuSCC (but not BCC) 
development; antibodies have been detected close to or at the time of cuSCC occurrence; 
antibodies against certain types correlated with β-HPV DNA presence in hair bulbs; individuals 
with cuSCC on chronically sun-exposed skin sites have turned out to be more likely to be 
positive for anti-β-HPV antibodies than those with cuSCC on sun-protected sites. 
 
Indication against an association between β-HPV infection and sporadic NMSC: 
- In contrast with what mentioned before, some studies have not found any differences in β-HPV 
DNA detection rates among NMSC, precancerous lesions, benign lesions and healthy skin 
- There is ample inconsistency among the β-HPV species and types found to be more associated 
with skin lesions, leading to an impossibility to correlate specific β-HPVs with NMSC or 
precancerous lesions 
- While high-risk α-HPV-associated cervical tumors harbor at least one genome copy per cell, 
viral load in β-HPV DNA-positive NMSC has been estimated to be around one genome copy 
per 20-5000 cells, indicating that not every tumor cell contains β-HPV genome, in according 
with what obtained from quantitative β-HPV DNA analyses in normal skin 
- Newer studies examining viral mRNA levels, have not supported a transcriptional mechanism to 
link HPV with cuSCC. 
- Not all seroepidemiological studies have shown a positive correlation between the presence of 
anti-β-HPV antibodies and NMSC (similar seroprevalences in cases vs controls), and in addition 
the presence of HPV DNA in tissue and antibodies to the same HPV type in the serum were not 
significantly correlated (Akgül, Cooke, and Storey 2006; Aldabagh et al. 2013; Meyer and 
Christophers 2000; Pfister 2003). 
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Epidemiological evidence in immunocompromised individuals 
In the case of primary immunodeficiency, the association of cutaneous HPV infection with the 
development of skin lesions is well established. A certain oncogenic role of β-HPVs has been 
clarified only in the EV setting, and patients with RHOH and MST1 deficiency, who exhibit an EV-
like phenotype, have recently been found to display high susceptibility to β-HPV infection.  
Other PID syndromes (e.g. SCID, WHIM), whose genetic backgrounds have been described and 
affect various aspects of immune function, are characterized by recurrent severe bacterial and viral 
infections since infancy and early childhood. As a result, these patients have a number of 
subsequent clinical manifestations, among which the predominant features are HPV-associated 
warts and also carcinomas. The detection of β-HPV infections in EV-like skin lesions from these 
individuals and their possible implication in the onset and development of these lesions, leaving 
open the possibility that these viruses play a role in cutaneous carcinogenesis affecting many of 
these subjects. 
Patients with acquired T-cell immunodeficencies, whether secondary (e.g. hematological 
malignancies, AIDS) or iatrogenic (e.g. OTRs undergoing long-term immunosuppressive therapy to 
prevent graft rejection) are all at increased risk of developing extensive, persistent and recurrent 
HPV-associated warty and keratotic skin lesions predominantly on sun-exposed sites; this is likely 
due to their impaired cell-based immunity to viral infections, including HPV. The persistence of 
HPV-associated wart-like lesions is a major issue for effective clinical management of these 
subjects and can affect their quality of life significantly.  
The consequence of acquired immunosuppression and the inability to clear viral infections can be 
far reaching because solid organ transplantation and HIV positivity increase the risk of secondary 
malignancies with a well documented viral etiology (e.g. Kaposi’s sarcoma associated with Human 
Herpesvirus 8 infection or post-transplant lymphoproliferative disorders associated with Epstein-
Barr Virus infection), that can arise following de novo viral infections or reactivation of latent 
viruses; Although this increase is presumed to be from the host’s inadequate control of what might 
otherwise be a harmless infection. (Aldabagh et al. 2013; Leiding and Holland 2012; Cubie 2013). 
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Organ transplant recipients 
Organ Transplantation is consider a modern medical miracle, and today there are over seventy 
thousand transplant a year worldwide and currently the 10 years survival it’s over the 80%. This 
increased survival rate has lead to the realization that the lifelong immunosuppressive treatment and 
the resulting modification of the immune system is associated with an increased risk of developing 
various cancers, with NMSC being the most common post-transplant malignancy. Over 30 different 
cancer types increase in incidence following post-transplant immunosuppressive therapy, with 
NMSC being the most frequent. In addition, the natural history of cancer in OTRs tends to be more 
aggressive than in the general population and these second tumors are the major cause of death in 
such patients. Although suppression of T-cell immunity and immunosuppressant drugs per se can 
exert carcinogenic effects, the most obvious mechanism of post-transplant tumorigenesis is that 
iatrogenic down-regulation of cell-mediated immunity unmasks the transforming activity of 
infectious agents resulting in the development of virus-related lesions  
Resembling an EV-like phenotype, OTRs develop long-lasting multiple wart-like and 
precancerous skin lesions such as AK with peculiar dysplastic features that are evident even in more 
benign lesions, and potential to evolve to NMSC; the prevalence of these lesions increases steadily 
each year after transplantation, and they can serve as early warning signs of cuSCC as they appear 
sooner after transplant. While the general population more commonly develops BCC as compared 
to the more invasive cuSCC (1:3) this ratio is inverted to a 4:1 ratio in favor of cuSCC in OTRs; 
cuSCC represents the most common de novo malignancy in the OTR setting, who exhibit a risk 65-
250-fold as great as that of immunocompetent subjects with a cuSCC frequency over 50% at 10 
years and over 80% at 20 years post-transplantation – while BCC is increased only 10-fold.  
Furthermore, cuSCC arising in OTRs can be higher aggressive compare with one developed by an 
immunocompetent individual. cuSCC increased rates of recurrence (13%), and the risk of lymph 
node metastasis developed earlier (mean 1.4 years). Almost 80% develop a second cuSCC within 3 
years, mostly developed in sun-exposed sites. 
The high burden of post-transplant cuSCC has a considerable impact on the quality of life, 
treatment costs and survival of OTRs overall. 
These lesion co-localizing with other wart-like and precancerous lesions, suggesting that their 
persistence favors malignant progression, and affect large skin areas in a process called field 
cancerization. Recent studies suggest a role for β-HPVs in the development of early premalignant 
lesions and NMSC due to an increased viral replication and gene expression in the context of a 
reactivation of previously unapparent β-HPV infections kept under control by cell-mediated 
immunity rather than increased de novo β-HPV infections. 
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Has been shown that OTRs have a β-HPV carriage even higher than the immunocompetent 
population, with frequent mixed co-infections and greater persistence especially in sun-exposed 
areas; as with the immunocompetent, certain types have been found to be the most prevalent on 
OTR skin (HPV 5, 20, 23, 24). Despite that, other studies have not found consistent differences in 
β-HPV DNA prevalence between OTRs and healthy subjects in both normal and lesional skin, and 
seroprevalence in this population is similar to that in immunocompetent individuals.  
Has shown for the general population, the evidence implicating β-HPVs in the pathogenesis of post-
transplant NMSC is mixed as well; several studies have linked β-HPV infection with cuSCC, but 
many of these have been small and others uncontrolled.  
 
Evidences in favor of an association between β-HPV infection and post-transplant NMSC: 
- Has been found a positive correlation between the detection of β-HPV DNA and anti-β-HPV 
antibodies (with type concordance) and the higher risk of developing cSCC 
- According to different studies, almost 90% of cuSCC and premalignant lesions are β-HPV 
DNA-positive. 
- higher prevalence of β-HPV DNA in sun-exposed areas has been reported to be associated with 
history of NSMC 
- β-HPV DNA has been detected more frequently in post-transplant cuSCC, and also BCC and 
premalignant lesions, and with more frequent mixed co-infections, compared to the 
immunocompetent counterpart 
- HPV 5 and 8 have turned out to be the most frequent types in post-transplant and occur more 
often in post-transplant cuSCC than in sporadic cuSCC 
- β-HPV DNA load has been shown to be higher in post-transplant cuSCC (but not BCC) than in 
sporadic cuSCC, with a positive correlation between viral load and time since transplantation  
- Few studies based on in situ hybridization have detected β-HPV DNA and RNA in cuSCC, 
suggesting active infection in the lesional tissue. 
 
Evidences against an association between β-HPV infection and post-transplant NMSC: 
- Two studies indicated a similar HPV DNA load in OTR cuSCC, BCC, pre-malignant, and 
benign lesions.  
- Low viral load and transcriptional activity have been found and in some other studies mRNA 
transcriptome high-throughput deep sequencing has failed to identify β-HPV expression in 
cuSCC (as in the immunocompetent counterpart)  
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- Some studies examining normal skin in individuals with and without history of NMSC have not 
found any significant difference in β-HPV DNA positivity between the two groups  
- For the most part seroprevalence in OTRs is similar to the immunocompetent, with the only 
difference being that reactivity to HPV 8 is increased in the immunosuppressed. (Akgül, Cooke, 
and Storey 2006; Aldabagh et al. 2013; Connolly et al. 2014; Dubina and Goldenberg 2009; 
Feltkamp et al. 2008; Harwood and Proby 2002; Hofbauer, Bouwes Bavinck, and Euvrard 2010; 
I Nindl and Rösl 2008; Pfister 2003; Oberyszyn 2008). 
 
Molecular mechanisms: the β-HPV oncoproteins 
Comparing High-risk α-HPV and β-HPV, the molecular mechanisms through which β-HPVs 
might participate in skin carcinogenic seems to differ from those underlying high-risk α-HPV-
induced cervical tumorigenesis; it appears that the functioning of β-HPV oncoproteins - E6 and E7, 
as E5 is not encoded by most β-HPV types – is more similar to that of low-risk α-HPV 
oncoproteins, with a great variability among different β-HPV species and types in the specific 
activities and efficiencies in interference with the functions of their cellular targets (E-m de Villiers 
1998).  
The β-HPV exhibit a weaker transforming potential, in contrast the high-risk α-HPV, of which 
oncoproteins expression overtly exert transforming and oncogenic activities in cellular and mouse 
models. E6 and E7 of most β-HPV types prolong of the lifespan of fibroblasts and primary human 
keratinocytes, either in monolayer or in organotypic raft cultures mimicking the structure of the 
epidermis, without efficient immortalization, inducing a moderate increase in proliferation and 
anchorage-independent growth and perturbing the normal cellular differentiation pattern; these 
effects are seen mainly when E6 and E7 are co-expressed and to different extents in different β-
HPV species and types. The β-HPV types displaying the highest transforming capabilities on the 
basis of in vitro and in vivo evidences are HPV 8 and 38. Experiments involving the expression of 
the HPV8 oncoproteins in primary human keratinocytes shown that the activity of these proteins is 
not sufficient for immortalization; however, E6 seems to be the dominant oncogene and is able to 
extend cell lifespan, induce anchorage-independent growth and alter cellular morphology, while E7 
causes cell hyperproliferation and abnormal keratinization.  
With the purpose to study the capability of HPV gene to perturb the keratinocyte differentiation and 
cell cycle, different transgenic mice models have been developed. Transgenic mice expressing the 
complete early region of HPV8 under the control of a keratinocyte-specific promoter spontaneously 
develop benign/premalignant skin lesions and some of them develop cuSCC; skin lesions arise only 
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arise in mice transgenic for E2, E6 and E6/E7 but not E7, suggesting that E7 alone is not sufficient 
to induce tumor growth having less oncogenic properties.  
Curiously E2 is so far not regarded as an oncogene of HPV. On the contrary, overexpression of 
genus-a HPV16- and HPV18-E2 results in cell-cycle arrest and apoptosis depending on the cell 
type. HPV11-E2- transgenic mice showed no histological changes in the skin. In contrast, HPV8-E2 
seems to act as an oncogene as E2-transgenic mice also develop skin lesions, even though to a 
lower extent, more slowly and with less severe malignant features; in vitro evidences have shown 
that HPV8 E2 can abrogate anoikis and promote anchorage-independent growth. The apparent 
tumorigenic properties of HPV8 E2 could be due to the ability of E2 to interact with cellular 
proteins and modulate the activity of host genes, with potential to affect the expression of critical 
cellular factors and thus favor transforming processes; Has seen also that in E2-transgenic mice, 
after a single solar-simulated UVA and UVB exposure, tumor growth thus started much faster and 
more frequently than in non-irradiated transgenics. This might have led to an upregulation of E2 
expression levels due to an activation of the keratin promoter, resulting in faster accumulation of E2 
effects. E2 might also contribute to tumor progression by interfering with the UV-damage response 
pathway and impeding cell-cycle arrest and apoptosis. This hypothesis is supported by the fact that 
E2 of HPV8 and/or other papillomaviruses interacts with several cellular proteins involved in DNA-
damage response. 
Co-expression of E6 and E7 from HPV 38 and 49 can immortalize primary human keratinocytes. 
HPV 38 E6/E7 transgenic mice spontaneously develop epidermal dysplasia and, after treatment 
with chemical carcinogens or chronic UV irradiation, precancerous lesions and malignant tumors 
(Akgül, Cooke, and Storey 2006; Akgül et al. 2007; Feltkamp et al. 2008; Pfister 2003; I Nindl and 
Rösl 2008; Schaper et al. 2005; Pfefferle et al. 2008; McLaughlin-Drubin, Meyers, and Munger 
2012; Tommasino 2014; Roman and Munger 2013). 
 
Has been recently investigated that E7 seems able to interact with Rb proteins in a large variation 
degree among different β-HPV species and types. However, the binding efficiency is lower than 
that of high-risk α-HPV E7 and only few β-HPVs, e.g. HPV38, are able to target Rb proteins for 
proteolytic degradation; in some β-HPV types it does, or at least destabilizes Rb proteins. In any 
case, E7 often fails to activate E2F-responsive genes, or it does very modestly.   
In human keratinocyte, HPV38 E7 also is able to disrupt the cell cycle regulation through the 
altered expression of p53-regulated genes. In particular, it promotes via an unknown mechanism 
nuclear translocation of the IκB kinase beta (IKKβ) kinase complex, which in turn associates with 
and phosphorylates ΔNp73α leading to its stabilization. ΔNp73α and IKKβ are part of an inhibitory 
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complex, together with two epigenetic enzymes, namely DNA methyltransferase 1 (DNMT1) and 
enhancer of zeste homolog 2 (EZH2), which are recruited to a subset of p53-regulated promoters 
and suppress their activation. The activity of HPV38 E7 therefore enhances the down-regulation of 
p53-dependent promoters, indirectly abrogating the p53 response upon UV damage and favoring 
the replication of cells harboring UV-induced genetic errors. ΔNp73α seems also to positively 
regulate hTERT promoter activity; this might account for an indirect E7-mediated telomerase up-
regulation underlying the immortalization of keratinocytes by HPV38 E6/E7.  
In both monolayer and organotypic cultures, HPV8 and HPV38 E7 have been shown to up-
regulate lipocalin-2, which bind and transport small essential factor or provide growth factor 
effects, thus modulating cellular response such as differentiation and proliferation. Deregulated 
expression of lipocalin-2 has been reported in several malignant conditions. HPV8 E7 can also 
enhance the expression of certain matrix-metalloproteases that can degrade components of 
basement membranes and extracellular matrix, possibly favoring tumor invasiveness (Akgül, 
Cooke, and Storey 2006; Harwood and Proby 2002; Tommasino 2014; Bauer et al. 2011; Roman 
and Munger 2013). 
 
Recent studies have been shown that only HPV49 E6 has the same ability as high-risk α-HPV E6 
to target p53 for ubiquitin-dependent proteasomal degradation via E6AP, otherwise β-HPV E6 seem 
to bypass G1-S checkpoint through different strategies.  
The β-HPV E6 proteins have evolved various mechanisms to subvert DNA damage-induced 
apoptosis and also to interact with different pro-apoptotic factors as the down regulation of kinase 
family member with a key role in the repair UVB DNA damage. Indeed, E6 can interfere with other 
components of p53-dependent pathways or selectively inhibit p53-induced pro-apoptotic mediators, 
and repress the expression of pro-apoptotic factors involved in other pathways (e.g. Fas); like E6 
from certain α-HPVs, β-HPV E6 can abrogate the anti-apoptotic function of Bak through its 
proteolytic degradation and resulting in an inhibition of UV-induced apoptosis.  
Interestingly, E6 from some β-HPV types can also interfere with DNA repair factors; for instance, 
E6 from HPV 8 and 1 abrogates the function of XRCC1 that is involved in repair of single-strand 
DNA breaks.  
HPV5 and HPV8 E6 have been shown to promote destabilization and proteolytic degradation of the 
histone-acetyltransferase p300, a critical co-activator for many transcriptional programs including 
p53; a role for this is implicated inhibition of differentiation and abrogation of the ATR/p53 
response to UV-induced DNA damage through a strong decrease in both mRNA and protein level 
of ATR, leading to the accumulation of UV-induced genetic alterations such as thymine dimers and 
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DNA double-strand breaks. In the case of HPV38 E6, the interaction with p300 result in the 
prevention of p53 acetylation and inhibition of the p53-dependent transcriptional response similarly 
to α-HPV E6. Furthermore this interaction appears to be essential for HPV38 E6/E7-mediated 
keratinocyte immortalization. 
A stable interaction of E6 protein and E6AP has been observed in certain β-HPV types (HPV 5, 
8, 38), and seem to be able to activate telomerase, but the underlying mechanisms may be different 
from those of high-risk α-HPV E6-mediated telomerase up-regulation.  
A recently discovered interaction between β-HPVs E6 protein and co-activators of Notch 
signaling has been shown to disrupt epithelial differentiation; notch signaling drives terminal 
differentiation of keratinocytes and acts as tumors suppressor in epithelial cancers. Notch signaling 
between adjacent cells affects the developmental fates of those cells, linking the differentiation fate 
of a given cell to that of its adjacent neighbor. Notch1 and Notch2 genes are expressed in the first 
spinous layer and the Notch ligand, Jagged2, is expressed in the basal layer; Notch signaling occurs 
both at the basal-spinous cell junction and in the upper spinous layer where it drives terminal 
differentiation of the granular layer. Upon canonical Notch signaling, the Notch receptor is cleaved 
by the intramembranous γ-secretase protease, liberating the Notch intracellular domain that forms a 
complex with the RBP-J DNA-binding protein and p300; this complex then translocates to the 
nucleus, and this displaces a repressor histone-deacetylase complex and recruits the MAML1 co-
activator, thus converting the RBP-J complex from a transcriptional repressor to an activator.  
β-HPV E6 interact with MAML1, resulting in the repression of Notch-dependent transcriptional 
activation and the disruption of epithelial differentiation, which may favor β-HPV replication and β-
HPV-driven transformation of host cells.  
There is also evidence that both HPV38 E6 and E7 can activate NF-κB, leading to the up-
regulation of the inhibitor of apoptosis cIAP2 – as in the case of high-risk α-HPV E6 - which would 
be expected to confer some resistance to certain DNA damaging agents such as UV radiation and 
therefore increase survival of DNA damaged-cells. The consequences of NF-κB activation by E6 
are apparently complex and may depend on cell type; e. g. a recent study of high-risk α-HPV E6 
indicated that NF-κB activation by E6 in ectocervical cells increases proliferation, whereas it may 
be inhibitory to growth of cells that are derived from the transformative zone, where most cervical 
cancers are developed. 
HPV8 has been shown to up-regulate certain oncogenic miRNAs and down-regulate tumor 
suppressive miRNAs in mice transgenic for the complete early region, suggesting that it may 
interfere with miRNA-mediated gene regulation to induce tumorigenesis (Akgül, Cooke, and Storey 
2006; Harwood and Proby 2002; McLaughlin-Drubin, Meyers, and Munger 2012; Wallace et al. 
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2012; Tommasino 2014; Vande Pol and Klingelhutz 2013; Hufbauer et al. 2011; Vandermark et al. 
2012). 
The “hit-and-run” model of β-HPV-associated skin carcinogenesis 
Based on the epidemiological and molecular data obtained so far, different paper support the so-
called “hit-and-run” mechanism of β-HPV-induced skin carcinogenesis. With this model is 
suggested a role of the viruses in early stages of the pathogenesis of NMSC - particularly cuSCC, 
which appear to be the NMSC type with stronger association to β-HPV infection - as cofactor and 
possibly transient carcinogens, being involved in tumor initiation in the presence of additional risk 
factors rather than in malignant progression or in the maintenance of the transformed phenotype as 
on the contrary occurs in high-risk α-HPV-driven cervical tumorigenesis. This hypothesis is 
supported by a large number of evidence. In the first place in non-Ev tumor tissues the viral load 
detected is low with a minimal gene expression, even in EV cuSCC the higher amount of viral DNA 
and gene expression is confined to few tumor cells. 
β-HPV oncoproteins present a lower transforming potential of compared to high-risk α-HPV 
counterpart. Another evidence is the impossibility to derive β-HPV DNA-positive cell lines from 
EV cuSCC because of the early loss of viral DNA (also in organotypic raft cultures), unlike the case 
of high-risk α-HPV DNA-positive cervical cancer-derived cell lines. Indeed the lack of evidence for 
β-HPV DNA integration in tumor cells, which on the contrary is a pivotal event in high-risk α-
HPV-induced cervical cancer. 
In this context, β-HPV oncogene expression could be a condition facilitating a transforming 
process previously triggered and subsequently carried on by other tumorigenic factors such as UV 
exposure. In individuals with a predisposing background characterized by the pre-existence of UV-
dependent genetic and epigenetic alterations in sun-exposed skin (e.g. loss-of-heterozygosity in 
tumor suppressor genes), β-HPVs persistently present in epidermal basal stem cells are likely to 
stimulate cell proliferation and inhibit DNA damage-induced apoptosis, therefore enhancing the 
propensity to accumulate further UV-induced genetic alterations – such as missense mutations of 
the of the gatekeeper suppressor gene p53 and activating mutations of the H-Ras proto-oncogene, 
both of which predispone to cuSCC; the subsequent malignant progression could thus only be due 
to additional DNA damage events independent on viral oncoprotein activity. In this scheme, could 
be no longer required the β-HPV persistence when cells are already initiated toward malignancy, 
and in more advanced stages of the carcinogenic process the viruses might finally be lost. 
(Akgül, Cooke, and Storey 2006; Connolly et al. 2014; Harwood and Proby 2002; Pfister 2003).  
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The link between UV radiation and NMSC was clearly highlighted in several studies. UV 
radiation plays and important aetiological role in skin carcinogenesis, underlying the pathogenesis 
of both NMSC and melanoma. UV exposure induces DNA damage by causing mutation in key 
genes. Specifically UV-B irradiation is able to induce the formation of pyrimidine dimers and other 
types of photoproducts, which through mainly p53-mediated responses normally either provoke cell 
cycle arrest and efficient DNA repair or induce an apoptotic program resulting in the eradication of 
deleterious cells. If DNA damage exceeds the capacity of host intrinsic repair, the accumulation of 
gene mutation in key cellular pathways is the force driving tumourigenesis in UV-induced skin 
cancer. 
Although the most important environmental risk factor for cuSCC is cumulative sun exposure, 
according to the hit-and-run model it appears that β-HPVs may act as co-carcinogenic factors. The 
synergy between UV light and active β-HPV infection is clear in the case of EV patients, who 
develop β-HPV-associated tumors in sun-exposed skin sites. The relative contribution of β-HPV 
might be greater in geographical areas characterized by lower sun-exposure.  
A weigh of data suggesting that β-HPVs, especially by means of the E6 oncoprotein, can inhibit 
both apoptotic pathways triggered by UV-induced DNA damage and repair of DNA damage itself, 
favoring a condition of genetic instability that may lead to the accumulation of mutations in proto-
oncogenes and tumor suppressor genes and subsequently to host cell transformation. UVB mediated 
apoptosis preferentially deleted DNA-damaged unmutated cells, allowing the β-HPV-infected 
keratinocytes to selectively proliferate in to the vacant niche. This might enable the amplification of 
apoptosis-refractory cells, which then could acquire further UV-induced somatic mutations (e.g. 
p53 and H-Ras mutations) that cannot eliminate because of the interference of E6 with the DNA 
repair machinery. The expansion of this cell population can result in the tumor progression, in 
which the viruses are likely not to be involved any longer (Figure 5).  
UV light has been observed to promote viral gene expression and life cycle progression, in 
particular in the case of HPV8 and 5. As results we have a high-level UV-responsive oncogene 
expression, which in turn is likely to amplify the deleterious effects due to UV radiation itself.  
Moreover, repetitive painful sunburns followed by epidermal regeneration of the skin from the 
underlying hair bulb could result in β-HPV amplification in individuals carrying latent infections, 
which then might drive the onset of transforming processes through high-level oncogene expression 
following viral life cycle reactivation. 
UV radiation not only have impact on the cell cycle directly; UV light is known to promote local 
immunosuppression disabling the tumor surveillance mechanisms that would otherwise recognize 
highly antigenic cutaneous lesions; leading the suppression of the local cell-mediated immunity and 
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interfering with the antigen presentation. One reasonable hypothesis is that UV-induced local 
immunosuppression promotes permissiveness to β-HPV infection; this would be consistent with the 
higher infection rates and viral loads in sun-exposed skin sites found by several epidemiological 
studies and could further account for a synergistic interplay between sun-exposure and β-HPV 
activity (Akgül, Cooke, and Storey 2006; Aldabagh et al. 2013; Bouwes Bavinck, Plasmeijer, and 
Feltkamp 2008; Feltkamp et al. 2008; Pfister 2003). 
 
It is important consider that all these proposed mechanisms may not have a relevant role in the 
above epidermal layers where cells have a short lifespan, but such effects could be significant in the 
follicular basal stem cells. Indeed, the persistent localization of β-HPVs in these cells – which may 
be the source of skin cancers – is likely to allow the acquisition of a condition of genetic instability 
that might convert them into cancers stem cells (Akgül, Cooke, and Storey 2006).  
 
      
 
Figure 5. Model of the roles of UV radiation and β-HPV infection in skin carcinogenesis. β-HPV infection 
may act as an initiator mechanism for cuSCC development, in combination with UV light, on sun-exposed 
body sites. UV exposure leads to DNA damage in skin cells. In β-HPV-infected cells, E6 is likely to promote 
retention of DNA damage and protect cells from UV-induced apoptosis. Normal cells that are fully 
competent for apoptosis might be preferentially deleted following UV damage, allowing clonal expansion of 
β-HPV-containing cells. Accumulation of genetic damage would then allow cells to progress to cuSCC 
independently of the proliferative and mutagenic effects of β-HPV infection (Akgül, Cooke, and Storey 
2006). 
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Future implications  
Therefore, future epidemiological studies are needed to resolve the conflicting evidence on the 
association between β-HPV infection and cuSCC development; and also further investigation on the 
relation between keratinocyte stem cells and β-HPV are needed to understand if these viruses play 
an active role the skin carcinogenesis and which is the underlying molecular mechanisms. 
On the basis of the epidemiological and biological data obtained so far, it appears that the β-HPV 
types with greater oncogenic properties are HPV 5, 8 and 38; HPV 5 and 8 are the only β-HPV 
types currently regarded as possible carcinogens driving the development of cuSCC, even though 
this evidence is linked to the setting of EV only.  
Resolving the conflicting evidence on the β-HPV involvement in the pathogenesis of cuSCC, 
along with the identification of high-risk β-HPV types, will have important implications for 
screening, prognosis and the development of adequate therapeutic and preventive strategies; e. g. 
the development of direct antiviral agents or small molecule inhibitors of viral proteins to prevent 
interaction with and disruption of cell cycle regulatory proteins. Developing new 
immunosuppressive strategies to address simultaneously the risk of allograft rejection and 
prevention of cancer in the OTR.  
Furthermore, early vaccination against certain types may decrease future disease burden, 
especially in at-risk patients like OTRs where no specific treatments for HPV-associated wart-like 
lesions are currently available; some studies for the development of vaccines against the putative 
high-risk β-HPV types such as HPV 5 and 8 are already ongoing in Australia.  
In case that β-HPVs are necessary for skin carcinogenic processes or act just as weak cofactors, 
the clarification of any viral mechanisms in cuSCC development would lead to enhanced treatment 
options based on new molecular targets for intervention and a reduction of the significant healthcare 
costs associated with these cancer types (S Tuttleton Arron et al. 2011; Aldabagh et al. 2013) . 
 
HPV life cycle biomarkers for the visualization of active infection patterns 
The highly regulated pattern of gene expression that characterizes HPV life cycle provides a 
basis for the selection of biomarkers that may be a useful tool to visualize the presence of active 
infections in lesional tissues through immunostaining procedures, with possible diagnostic 
applications. This has been deeply investigated for α-HPV types associated with lesions; in 
particular, the analysis of the expression patterns of certain viral gene products may allow the 
severity of the underlying disease to be predicted, and the detection of those products might 
improve cervical screening.  
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The key life-cycle markers used for the visualization of the HPV infection are E4, E6/E7 and the 
coat proteins L1 and L2. These proteins are usually co-visualized with the products of E2F-
activated genes such as MCM, Ki-67, and PCNA; also used as surrogate markers of E7 expression. 
All these gene products are normally restricted to the basal layer in uninfected epithelium and are 
markers of cell cycle entry rather than cell division. Usually associated with E4 expression, DNA 
FISH analysis is another methodic used to detect the viral genome amplification. 
Although E1, E2 and E5 expression is thought to accompany the expression of E4, these proteins 
have proved difficult to detect in HPV-induced lesions. E1 is thought to be a very minor gene 
product, as codon usage within the E1 ORF is sub-optimal and E1 transcripts are difficult to detect. 
E2 by contrast, is thought to be expressed more abundantly. The E2 expression has been clearly 
identified in bovine warts caused by BPV, but its identification in human lesion is currently less 
conclusive. The detection of E5 by immunostaining is compromised by the fact that the protein is 
predominantly membrane bound, therefore limiting epitope availability; as with E2, there are only a 
limited number of studies that have investigated E5 distribution in vivo, and it is difficult to be 
certain as to its precise expression pattern (Middleton et al. 2003; Doorbar 2007; Doorbar et al. 
2012). 
The detection of the High-risk α-HPV life cycle markers in cervical cancer is related to the different 
grades of the disease (summarized in Figure 6). During productive infection as it occurs in CIN1 
lesions, cell cycle markers such as MCM are expressed preferentially in the basal and parabasal 
layers, with their presence being a direct consequence of E7 activity; these E7 surrogate markers 
localize to the nucleus, while for E7 both cytoplasmic and nuclear localization have been reported. 
In the mid layers, proteins necessary for genome amplification become elevated in these cells, 
allowing genome amplification to occur, also supporting the expression of the viral E4 protein. 
E4 appears in the cytoplasm as MCM signal begins to decline in the mid-upper epithelial layers of 
the lesion and is generally a marker of low-grade disease; E4-positive cells are typically in S-phase 
or G2-phase and usually display detectable viral DNA. Cells supporting genome amplification 
present a stain positive with only a narrow overlapping for E4 and E7 / E7 surrogate markers, 
probably due to the down-regulation of E7 expression by increased E2 levels thought to accompany 
E4. The final stage in the virus life cycle involves the packaging of viral particles starts only in cells 
that have already undergone genome amplification follows genome amplification, and is marked 
eventually by the appearance of the capsid proteins (L1 and L2) in the nuclei of a subset of E4-
positive cells in the upper epithelial layers. 
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Low-risk α-HPV life cycle markers in associated lesions show expression patterns similar to those 
found in early productive high-risk α-HPV infections; MCM is apparent only in the upper epithelial 
layers where E4 also becomes abundant. 
E4 expression is gradually lost during cervical neoplastic progression, remaining restricted to 
isolated pockets close to the upper epithelial layers; the extent of E4 expression is progressively 
decreased and correlates inversely with disease severity, suggesting that the assessment of its 
distribution in the context of the lesions could be exploited as a useful tool for disease staging. 
Consistently with the reduction in E4 expression, viral DNA is usually not detected in HSIL, and 
cervical cancer as viral replication is increasingly driven down. 
E7 expression becomes deregulated during disease progression and unlike E4 is more easily 
detectable in high-grade neoplasia than in productive lesions. E7 / E7 surrogate markers extend to 
the epithelial surface (e.g. MCM is elevated to different extents in neoplasia); the thickness of the 
E7 / E7 surrogate marker-expressing layer increases markedly with increasing disease severity from 
CIN1 to cervical cancer. 
In high-risk α-HPV infections, p16ink4a is unable to exert a regulatory effect as S-phase entry is 
stimulated by E7 rather than cyclinD/Cdk; the absence of effective inhibition of cell cycle 
progression by p16ink4a can lead to its accumulation in the cell and to an elevation of E7 surrogate 
markers throughout the infected epithelial layers. Detectable p16ink4A is also regarded as a 
surrogate marker of elevated E7 expression, and can be seen in some CIN1 lesions as well as in 
CIN2 and CIN3; p16ink4a expression is used for routine diagnostic purposes as marker of high-risk 
α-HPV infection in cervical or oropharyngeal cancers. 
As HSIL and cervical cancer are characterized by abortive infections, expression of capsid proteins 
L1 and L2 occurs rarely because viral particles are not produced and cannot be detected by 
immunostaining (Doorbar 2007; Doorbar et al. 2012; Griffin et al. 2012). 
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In a recent study has characterized for the first time β-HPV life cycle events in skin tumors from 
EV patients – the human model of β-HPV-induced skin cancer – showing how changes in E4 
expression patterns relate to disease severity.  
Abundant cytoplasmic E4 expression and viral DNA have been detected in differentiating cells 
undergoing viral genome amplification, especially in lower-grade lesions. Interestingly, E4 
expression has also been seen in PCNA-positive basal cells in some more dysplastic EV skin 
tumors; in these lesions, E4 has been found to extend throughout the full thickness of the epithelium 
and to be apparent in the markedly atypical cells. The loss of such staining at the tumor border 
suggests a distinct type of E4 deregulation that may be exploited as a marker of viral expression 
during β-HPV-associated skin cancer progression (Borgogna et al. 2012). 
 
 
 
 
Figure 6. In the different stages of cervical cancer is possible visualize 
different expression patterns of high-risk α-HPV life cycle biomarkers. 
The most useful biomarkers to visualize active infection are E7 (along 
with E7 surrogate markers), E4 and L1/L2; viral genome amplification 
can also be detected by DNA FISH analysis. In CIN1 lesions typically 
associated with productive infection, E7 positivity is found in the lower 
epithelial layers, while cytoplasmic E4 expression and viral DNA are 
evident in the mid-upper epithelial layers where viral genome 
amplification is occurring; L1/L2-positive nuclei can be seen in some 
E4-positive cells in the more superficial layers. During disease 
progression, E7 expression increasingly extends to the whole thickness 
of the epithelium while E4, viral DNA and L1/L2 are progressively lost, 
as expected in abortive infection. Modified from Doorbar et al., 2012. 
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Influence of HPV gene expression on keratinocytes differentiation in in-vivo 
model. 
Different transgenic mice models have been developed so far for investigate the role of HPVs in 
skin cancer. The first transgenic mouse model for skin-associated HPVs was generated in 1992 at 
the University of Birmingham Medical School, by Searle’s group. In this model the HPV-1 early 
region was placed under the control of epidermis specific promoter from keratin genes. 
Morphological alterations of the normal epithelial differentiation have been observed, the effect was 
greatest on the tail, where the epithelium became hyperproliferative in appearance, with several 
layers of irregular or cuboidal cells above the basal layer, an increase in the total number of cell 
layers, and abnormal cornification. A similar transient flaky appearance also associated with 
epidermal hyperplasia was observed on other regions of the skin around 7 days of age. It is worth 
mention that this transgenic mice didn’t able to develop any spontaneous skin lesion. 
Pfister and co-worker, to further evaluate the possible contribution of β-HPV in a proliferative 
tissue compartment during carcinogenesis, established a transgenic mouse model where the 
complete early region of HPV8 are expressed in the undifferentiated basal layer of epithelia under 
the control of the Keratin 14 promoter. In this transgenic mice the first phenotypic alterations 
detectable started around 14 weeks of age showing the presence of tumor like growth on the back 
with hair loss, hyperkeratosis and ulceration.  
Almost all of these HPV8 trangenic mice (91%) developed without any treatment with physical or 
chemical carcinogen, single or multifocal benign tumors, characterized by papillomatosis, 
acanthosis, hyperkeratosis, and varying degrees of epidermal dysplasia; furthermore 6% of this 
transgenic mice developed SCC. The rapidity of skin tumor development in the mice is certainly 
related to the permanent expression of the HPV8 early genes in all proliferation competent 
keratinocytes driven by the K14 promoter. With this model could thus be shown for the first time 
that expression of a β-HPV leads to skin cancer development without exposure to any further 
physical or chemical carcinogens. Using transgenic technology, several others mouse lines have 
been developed expressing HPV8 E2 protein or also E6/E7 from other β-genotypes, such as HPV38 
and HPV20 but HPV8 has thus far been the only cutaneous HPV type found to induce skin cancer 
completely on its own in the absence of any additional co-carcinogenic treatment, making it a good 
candidate to investigate how β-HPV gene expression can influence the keratinocytes differentiation 
(Tinsley, Fisher, and Searle 1992; Schaper et al. 2005; Akgül, Cooke, and Storey 2006; Viarisio et 
al. 2011; De Andrea et al. 2010). 
 
Materials & Methods 
59 
 
MATERIALS & METHODS 
 
 
 
β-HPV detection in a cohort of Organ Transplant Recipients 
 
Collection of skin lesion specimens  
All formalin-fixed and paraffin-embedded (FFPE) blocks analyzed in this study were retrieved 
from the medical material archives of the University-Hospital in Novara.  
From the cohort of kidney transplant recipients (KTRs) a total amount of 111 FFPE blocks were 
obtained from 79 skin lesions. As the lesions were of different sizes, the samples were either split 
into more section or kept intact. A single block was available for 51 lesions, denominated “whole 
lesion”. The remaining 28 lesions were sectioned in two or more blocks, and corresponded to the 
core and edges of the lesion. All lesions were excised from 17 KTRs (16 male and 1 female), 
receiving transplants between 1998 and 2009. However, one patient among them also had heart 
transplant twice. 
Data on skin lesion development and characteristics were retrieved from pathology archives and 
clinical records. The mean length of patient follow-up following kidney transplantation was 15 
years and 4 months±7 years and 8 months. 
In the present study a single FFPE block from a wart-like lesion of a patient with 
epidermodysplasia verruciformis (EV) was used as a positive control.  
Written informed consent was obtained by all subjects according to the Declaration of Helsinki, 
and approval was obtained from local ethic committee. 
 
β-HPV DNA detection and genotyping  
DNA extraction has been performed from three consecutive 10 µm-thick sections which were 
retrieved from FFPE blocks, purified DNA was obtained by means of the QIAamp Tissue Kit 
(Qiagen) according to the manufacturer’s instructions. To prevent cross-contamination, the 
microtome was thoroughly cleaned following the sectioning of each block and a new blade installed 
for the next one. 
β-HPV DNA detection and genotyping was carried out using the PM-PCR reverse hybridization 
assay (Skin β-HPV prototype research assay; Diassay BV, Rijswijk, The Netherlands), as 
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previously described (De Koning et al 2006). The method was designed to identify the 25 
established β-HPV types (i.e., HPV 5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36, 37, 38, 47, 
49, 75, 76, 80, 92, 93, 96). PM-PCR amplification, generating a biotinylated amplimer of 117 bp 
from the E1 region, was carried out following all the precautions indicated by the manufacturer to 
avoid recurrence of cross-contamination.  
Briefly, PM-PCR reaction was performed in a final reaction volume of 50µL, containing 10µL of 
the isolated DNA, 2.5mM MgCl2, 1x GeneAmp PCR buffer II, 0.2mM deoxynucleoside 
triphosphates, 1.5 U Amplitaq Gold DNA polymerase and 10µL of the PM primer mix. The PCR 
reaction was performed as follows: 
- 9’ pre-heating step at 94oC  
- 35 amplification cycles:  
- 30” at 94oC,  
- 45” at 52oC 
- 45” at 72oC 
- 5’ final elongation step at 72oC.  
As a positive PCR control, a β-HPV plasmid clone was included. Identification of the amplified β-
HPV types was performed by reverse hybridization analysis of the amplimers on genotyping strips 
provided by the manufacturer. In each strip a probe line contains a mix of “universal” β-HPV 
probes: in some cases these probes are positive without a specific β-HPV probe being positive, 
indicating the presence of an unspecified β-HPV genotype.  
 
Antibodies  
To generate polyclonal antibodies against the E4 proteins of the β-HPV genotypes, DNA 
comprising the full-length spliced E1^E4 gene (Doorbar, 2013) was amplified by PCR from an 
HPV5 genomic clone isolated from an EV patient. For PCR amplification of the E1^E4 coding 
region, the following primers were used:  
- E4HPV5 forward: 
5'GGAATTCAGAATGACGGATCCTAATTCTAAAGCTCCACGCCTCCAGGGTCGCCAG
GAG-3′  
- E4HPV5 reverse:  5′GCTCTAGAGTCGACCTATTACTGGGGGGTCGCGAGCTTCTTCCA-
3′ 
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The forward primer included an EcoRI site (underlined) upstream of the ATG initiation codon, 
while the reverse primers contained a SalI sequence (underlined). 
To generate polyclonal antibodies that can broadly identify the L1 proteins of the β-HPV 
genotypes, sequence alignments were first carried out and the highly conserved region between 
aminoacid 200 and 300 was chosen. The corresponding coding region within the full length L1 gene 
was amplified by PCR from the same HPV5 genomic clone used for the generation of anti-HPV5 
E1^E4 antobodies. For PCR amplification, primers with the following sequences were used:  
- L1 forward:  5´-CGCGGATCCCGTCTGTATCCAAAACCCTTG-3´  
- L1 reverse:  5´-CCGCTCGAGTTATCCTATAGTCTTTTGAGCTTG-3´  
The forward primer included a BamHI site (underlined) upstream of the ATG initiation codon, 
while the reverse primers contained a XhoI sequence (underlined).  
 
In both cases, amplimers were cloned into the pGEX-4T-2 vector (GE Healthcare) using 
standard methods, and then expressed in the Escherichia coli host BL21. GST-HPV5 L1 and GST-
HPV5 E1^E4 fusion proteins were dialyzed overnight at 4°C in 50mM Tris-HCl pH 8.5, 0.5% β-
mercaptoethanol and 3M urea, and then re-dialyzed for 12h at 4°C in 50mM Tris-HCl pH 8.5 and 
protease inhibitors (Sigma). Anti-sera were raised by injecting rabbits with the dialyzed GST-HPV5 
L1 and GST-HPV5 E1^E4 fusion proteins. Rabbits were immunized at multiple subcutaneous sites 
with 250 µg of protein in Freund's complete adjuvant, followed by booster immunizations at 14-day 
intervals with the 250 µg antigen in Freund's incomplete adjuvant. Animals were bled 1 week after 
the fourth immunization and serum immunoglobulins obtained by precipitation with 45% saturated 
ammonium sulfate. The precipitate was then resuspended in PBS and purified on a protein A 
affinity column (GE Healthcare) according to the supplier’s specifications. Antibody titres were 
evaluated by ELISA. Preimmune serum was collected prior to the initiation of the immunization 
protocol and was used as a control in the immunostaining experiments. 
To verify the reactivity spectrum of anti-HPV5 E1^E4 antibodies amongst different β-HPV 
genotypes, Western blot analysis was performed for different β-HPV E1^E4 recombinant proteins. 
The antibodies were able to cross-react with many genotypes belonging to β1 species including 
HPV 8, 14, 20, 24, 25, 36. 
 
Antibodies for the proliferation marker minichromosome maintenance protein 7 (MCM7), a 
commercial monoclonal antibody was used according to the manufacturer’s instructions. 
(Neomarkers, Fremont, CA, USA). 
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Immunofluorescent detection 
Consecutive 5-µm thick tissue sections were cut from FFPE blocks onto Superfrost™ Ultra Plus 
Adhesion Slides (Thermo Scientic), incubated at 56°C for 50’ to increase adhesion on slide surface, 
dewaxed and rehydrated as follows: twice in xylene for 15’ each, twice in 100% ethanol for 10 min 
each, followed by a series of graded ethanol (95%, 90%, 75%) for 5’ each and finally 1X PBS for 
5’.  
To quench endogenous peroxidase, tissue sections were incubated with 3% hydrogen peroxide 
diluted in 1X PBS for 15’ at room temperature with shaking and then rinsed in 1X PBS for 5’. For 
antigen unmasking, slides were placed in a glass slide holder and pre-soaked for 5 min in 10mM 
citrate buffer at pH 6.0 (Vector Laboratories) diluted in bidistilled water, then heated for three times 
in microwave oven at 750W for 4’30” each with 1’ intervals inside a pressure cooker and finally 
cooled for 20’ and washed for 5’ in 1X PBS.  
All the subsequent incubation steps performed in the staining procedures described below were 
carried out putting the slides inside a dark humidified box. 
 
For immunofluorescent detection of β-HPV E4 coupled to DNA-FISH, DNA probes consisting 
of complete cloned β-HPV genomes were biotin-labelled using the Biotin-Nick Translation Mix 
(Roche) according to the manufacturer’s instructions. Biotinylated probes were then 1:25 diluted in 
hybridization buffer (50% formamide, 5X SSC, 0.1% Tween-20, 0.2 ng/µl yeast tRNA) and the 
probe mix was added to tissue sections previously allowed to air dry after antigen unmasking. After 
was lowered a cover-slip onto tissue sections, and sealed with Rubber Gum (Rubbercement) to 
avoid evaporation. The slides were heated on a hot block for 5’ at 95°C for DNA denaturation and 
then cooled on ice and finally incubated overnight at 37°C for probe annealing.  
The following day, stringent washes with pre-warmed SSC solutions at decreasing concentrations 
were performed for 10’ each as follows: 2X SSC (allowing also the peeling off of rubber gum and 
loosening of cover-slips), formamide wash buffer (50% formamide, 2X SSC, 0.05% Tween-20), 1X 
SSC, 0.5X SSC. Tissue sections were subsequently blocked with 10% NGS / 1X PBS for 1 h at 
room temperature. After blocking, primary rabbit polyclonal anti-HPV5 E1^E4 antibody was 
1:1000 diluted in 5% NGS / 1X PBS and added onto tissue sections overnight at 4˚C. The following 
day, slides were then washed in 1X PBS / 0.05% Tween-20 for 5’ at room temperature with 
shaking. Next, a mixture containing 1:100 diluted streptavidin-HRP (TSATM Tetramethylrhodamine 
System, PerkinElmer), 1:200 diluted FITC-labelled secondary anti-rabbit antibody (Invitrogen), and 
DAPI as nuclear counterstaining diluted in 1X PBS was added onto tissue sections and slides were 
incubated for 1 h at room temperature. After a 5’ wash in 1X PBS, TSA fluorescent substrate 
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(TSATM Tetramethylrhodamine System, PerkinElmer) prepared according to the supplier’s 
specifications was added for 10’ at room temperature, followed by a 5’ wash in 1X PBS. After final 
wash twice 5’ in 1X PBS, slides were mounted with ProLong® Gold Antifade Mountant (Life 
Technologies). 
 
For immunofluorescent detection of β-HPV E4 coupled to MCM7, the tissue, sections after 
antigen retrieval, were blocked with 10% NGS / 1X PBS for 1 h at room temperature. After 
blocking, primary mouse monoclonal anti-MCM7 antibody was 1:200 diluted in 5% NGS / 1X PBS 
and incubated onto tissue sections overnight at 4°C. 
 The following day, slides were washed in 1X PBS / 0.05% Tween-20 for 5’ at room temperature 
with shaking and tissue sections incubated with secondary biotinylated universal antibody (Vector 
Laboratories) for 30’ at room temperature. For amplified the signal, the slides were washed 5’ in 1X 
PBS, and then incubated with the Avidin/Biotin Blocking Kit (Vector Laboratories; 3.6 µl Avidin 
Solution + 3.6 µl Biotin Solution in 400 µl 50 mM Tris-HCl pH 7.5) for 30’ at room temperature. 
After a 5’ wash in 1X PBS, streptavidin-HRP (TSATM Tetramethylrhodamine System, PerkinElmer) 
1:100 diluted in 1X PBS was added onto tissue sections for 1 h at room temperature. Proceeding 
with 5’ wash in 1X PBS, TSA fluorescent substrate (TSATM Tetramethylrhodamine System, 
PerkinElmer) prepared according to the supplier’s specifications was added for 10’ at room 
temperature, followed by a further 5’ wash in 1X PBS. Tissue sections were subsequently incubated 
overnight at 4°C with primary rabbit polyclonal anti-HPV5 E1^E4 antibody 1:1000 diluted in 5% 
NGS / 1X PBS.  
On the third day, after a 5’ wash in 1X PBS/ 0.05% Tween-20 at room temperature with shaking, 
FITC-labelled secondary anti-rabbit antibody (Invitrogen) 1:200, together with nuclei 
counterstaining DAPI diluited in 1X PBS was added onto tissue sections and slides were incubated 
for 1 h at room temperature. After wash twice in 1X PBS for 5’, tissue sections were finally 
mounted with ProLong® Gold Antifade Mountant (Life Technologies). 
 
For immunofluorescent detection of β-HPV L1, tissue sections after antigen retrieval were 
blocked with 10% NGS / 1X PBS for 1 h at room temperature. After blocking, tissue sections were 
incubated overnight at 4°C with primary rabbit polyclonal anti-HPV5 L1 antibody 1:1000 diluted in 
5% NGS / 1X PBS.  
The following day, after a 5’ wash in 1X PBS / 0.05% Tween-20 at room temperature with shaking, 
TexasRed-labelled secondary anti-rabbit antibody (Invitrogen) 1:200 together with nuclei 
counterstaining DAPI diluted in 1X PBS was added onto tissue sections and slides were incubated 
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for 1 h at room temperature. After twice wash 5’ in 1X PBS, tissue sections were finally mounted 
with ProLong® Gold Antifade Mountant (Life Technologies). 
 
For assessment of histological features, slides analyzed by anti-HPV5 E1^E4 / anti-MCM7 
antibodies were disassembled and stained with hematoxylin and eosin (H&E) as follows: 
hematoxylin 10’, wash in tap water for 5-10’, eosin for 5’ and a final quick wash in tap water. 
Tissue sections were then dehydrated in a series of graded ethanol (75% for 20”, 95% for 20”, 
100% for 2”), diaphanized twice in xylene for 2” each and finally mounted with VectaMount 
Permanent Mounting Medium (VECTOR Laboratories). 
 
Images were acquired using a digital scanner (Pannoramic MIDI, 3D Histech Kft) allowing 
overlay of immunofluorescent and H&E staining patterns. 
 
 
β-HPV influence on keratinocyte differentiation in HPV8 transgenic 
mice 
 
Genotyping of progeny 
To identified HPV8 transgenic from wild type littermates, genomic DNA was isolated from tail 
biopsies of 7-day-old mice using the QIAamp Tissue kit (Qiagen) or from 0.5% dispase II (Roche)– 
and trypsin (Sigma)–treated full-thickness skin. Samples of genomic mouse DNA were analyzed for 
presence of the transgene by PCR, using primers that bind outside the early genes E6 and E7 (5V-
CAATTTTCCTAAGCAAATGGAC and 3V- CACTACATTCAGCTTCCAAAATACA), and ∼0.3 
µg of DNA was analyzed in a final volume of 25 µL using REDTaq ReadyMix PCR Reaction Mix 
(Sigma). PCRs were performed on a MJ PTC-200 thermal cycler (Bio-Rad) using the following 
protocol:  
- 2’ denaturation step at 94°C  
- 35 amplification cycles: 
- 45” at 94°C  
- 1’ at 50°C 
- 1’30” at 72°C  
- 72°C for 7’ for a final extension  
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PCR products were separated by 2% agarose–TAE gel electrophoresis, and ethidium bromide 
staining was used to detect the separated bands. Mice were kindly provide by Herber Pfister’s group 
and housed in accordance with The Guide for the Care and Use of Laboratory Animals, in the 
animal facility at the University of “Piemonte Orientale”, Novara. 
 
Skin Samples 
Skin samples were collected from 5 HPV8 transgenic mice and 5 wild type littermates. For 
immunofluorescent experiments, skin samples were formalin-fixed in 10% neutral-buffered 
formalin (Sigma-Aldrich) over night at 4˚C. After a 5’ wash in 1X PBS, the samples were 
dehydrated by a series of grated ethanol (75%, 90%, 95) for 1 h each and then twice in 100% 
ethanol for 1 h each. Finally tissue samples were diaphanized twice in xylene for 1h 30’ and then 
paraffin embedded. 
Consecutive 5-µm thick tissue sections were cut from FFPE blocks onto Superfrost™ Ultra Plus 
Adhesion Slides (Thermo Scientific), incubated at 56°C for 50’ to increase adhesion on slide 
surface, dewaxed and rehydrated as follows: twice in xylene for 15’ each, twice in 100% ethanol for 
10 min each, followed by a series of graded ethanol (95%, 90%, 75%) for 5’ each and finally 1X 
PBS for 5’. Finally the sections were stained with hematoxylin and eosin (H&E) as follows: 
hematoxylin 10’, wash in tap water for 5-10’, eosin for 5’ and a final quick wash in tap water. 
Tissue sections were then dehydrated in a series of graded ethanol (75% for 20”, 95% for 20”, 
100% for 2”), diaphanized twice in xylene for 2” each and finally mounted with VectaMount 
Permanent Mounting Medium (VECTOR Laboratories). 
 
Whole mount protocol 
Whole mount is a well-established technique applied to characterize normal and genetically 
modified mice with skin defects. It has previously been determined that mouse tail epidermis is very 
informative, as robust whole mounts can be generated from any stage of the hair cycle. In addition, 
tail skin contains large hair follicles with clear anatomical features, which are ideal for microscopic 
visualization. In contrast however, the consistent generation of high-quality epidermal sheet for the 
dorsal epidermis is prevent by the fact that it is more fragile and contains a much higher density of 
hair follicles. Hair follicles in the tail grow as triplets and undergo cycles of growth with similar 
timing to dorsal follicles, although the degree of synchronization is less tight. 
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The epidermal whole mount protocol was established while working in the laboratory of Dr G. 
Patel (European Cancer Stem Cell Research Institute, Cardiff University, UK) as a visiting scientist, 
over a period of 7 months as part of the Ph.D program. 
Transgenic mice and wild type littermates, 5 each, were killed using an approved technique and 
the tails were removed by slicing with a scalpel at the point at the attachment to the body. Then the 
tail was slit with a sterile scalpel and using a pair of forceps the skin was peeled off from the 
underlying connective tissue.  
Using a petri dish as support, the skin was cut in different pieces of 5x5 mm2, almost 12 pieces were 
collected from a single tail, and incubated overnight with 2.5 ml of Neutral protease (Dispase®, 
Worthington Biochemical Corporation) 25U/ml in a 6-well plate; every well contained not more 
than 3 pieces. 
The following day the pieces of skin were placed on a sterile petri dish, and the intact epidermis 
sheet was gently removed from the dermis using two pairs of forceps. After that, the epidermal 
whole mounts were formalin-fixed in 10% neutral-buffered 2 h at room temperature. The samples 
were then stored for following immunofluorescent experiments in 1x PBS with 0.2% sodium azide 
at 4˚C. 
 
Immunofluorecent staining on epidermal whole mount samples 
This is the general protocol used to investigate different markers of stem cell subpopulations in 
the hair follicle of both transgenic and wild time mice. Stem cell markers were coupled with the 
proliferation marker Ki67.  
The complete list of primary and secondary antibodies used on epidermal whole mount samples is 
described Table 1. 
Each epidermal sheet was placed in an individual well of a 48-well tissue culture plate, and blocked 
with 100 µl of Blocking Buffer, (0.5% skim milk powder, 0.25% fish skin gelatin) in 1X Sodium 
Buffer (0.9% NaCl, 20 mM HEPES, pH 7.2), 30’ at room temperature. After the aspiration of the 
Blocking Buffer the epidermal sheets were incubated with the primary antibody diluted in Blocking 
Buffer, in gentle agitation overnight at room temperature. 
The second day the samples were carefully moved in a new well and washed 4 times for 45’ each in 
0.2% Tween 20 in 1X PBS. After the last washing the epidermal sheets were incubated with 
spieces-specific secondary antibodies diluted with also DAPI at a final concentration of 1 µg/ml, in 
Blocking Buffer. Tissue culture plates were covered with aluminum foil for the remainder of the 
protocol as the dyes are light-sensitive; secondary fluorescent antibodies were incubate over night 
with gentle agitation at room temperature.  
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The third day the secondary antibodies were aspirated and the epidermal sheet were washed 4 times 
for 45’ each in 0.2% Tween 20 in 1X PBS. After the samples were mounted on a microscope slide 
with the basal surface facing the coverslip using the ProLong® Gold Antifade Mountant (Life 
Technologies). 
 
Antibodies for keratinocyte stem cell characterization in hair follicle 
In the hair follicle there are at least 4 keratinocyte stem cell populations in the hair follicle that can 
recreate the entire interfollicular epidermis and hair follicle, but in homeostasis each one are 
responsible for the turnover of a area in the hair follicle and the adjacent overlying epidermis. 
 
Table 1. Complete list of stem cell markers used in the whole mount protocol. 
Name of marker 
⁄ stem cell 
population 
Diluition Company  Location in skin Stem cell properties References 
CD34 1:200 553731, BD Pharmingen 
Bulge region 
of mouse, 
external root 
sheath 
in human 
Used for enrichment of 
HF bulge keratinocytes ⁄ 
able to reconstitute 
epidermis 
(Blanpain et 
al. 2004; 
Trempus et 
al. 2003) 
 Lgr5+ cells 1:500 
NLS1236, 
Novus 
Biologicals 
Bulb region 
Contribute to all hair 
lineages  but not to SG 
and IFE 
(Jaks et al. 
2008) 
Lgr6+ cells 1:50 ab126747, Abcam Isthimus 
Prenatal Lgr6+ cells can 
form HF, SG and IFE, 
they are not the LRCs 
(Snippert et 
al. 2010) 
Lrig 1 1:100 AF3688, R&D Systems IFE, Isthimus. 
express Lgr6 but not the 
Lgr5 and CD34, and are 
able to 
reconstitute the IFE and 
SC 
(Jensen et al. 
2009) 
K15 1:50 
MA1-90929, 
Thermo 
Scientific 
Bulge region 
of HF of mice 
and human 
Capable of generating 
epidermis, 
HF and SG 
(Morris et al. 
2004) 
 
Immunofluorescent stainings of all the keratinocyte stem cell markers were performed in coupled 
with the proliferation marker Ki67, a commercial monoclonal antibody used according to the 
manufacturer’s instructions (ab16667, Abcam). 
Images were acquired using The Leica DMI6000 B inverted microscope (Leica Microsystem) and 
analyzed using ImageJ, a public domain, Java-based image processing program developed by 
Wayne Rasband at the National Institutes of Health. 
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β-HPV detection in Kidney transplant recipients (KTRs) 
 
Characteristics of the study cohort. 
The cohort of KTRs in this study is composed of 17 patients (16 males and 1 female) and is 
described in Table 1. Patients were numbered in ascending order based on the number of tumors 
each developed. A total of 79 skin lesions were recorded in this study. The median time taken for of 
skin lesions to develop was 7 ± 5 years after transplantation. Within 10 years from transplantation, 5 
patients developed more than 5 lesions (patients 13–17), mostly in sun-exposed sites, confirming 
sun exposure to be a major contributor to epithelial transformation. Multiple skin lesions (range 2-
14) arose in a total of 10 patients. The proportion of lesions affecting sun-exposed skin areas (head, 
hands and forearms) was 59 out of 79 lesions (75%).  
Histologically, the cutaneous lesions included:  
- High-grade tumors 
- basal cell carcinoma (BCC) → n = 31 
- squamous cell carcinoma (SCC) → n = 14  
- Precancerous lesions  
- actinic keratosis (AK) → n = 19  
- keratoacanthoma (KA) → n = 7 
- Bowen’s disease (BD) → n=1  
- Benign lesions  
- seborrheic keratosis (SK) → n=7 
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Table 1. Baseline characteristics of the study cohort of kidney transplant recipients.  
Patients( Birth(date(
Tx(
date(
Years(after(transplantation( Follow(
Up(
(years)(
Total(n.(
of(
Tumours(1( 2( 3( 4( 5( 6( 7( 8( 9( 10( 11( 12( 13( 14( 15( 16( 17( 18( 19( 20( 21( 22( 23( 24( 25( 32(
1"M" 1961$ 2005$K$ $$ $$ $$ BCC*$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$     $$ $$ $$ 8$ 1$
2"F" 1946$ 1995$K$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ SCC$ $$ $$ $$ $$ $$ $$   $$   $$ $$ $$ 18$ 1$
3"M" 1952$ 1996$K$ $$ $$ $$ $$ $BCC$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$   $$   $$ $$ $$ 17$ 1$
4"M" 1939$ 1994$K$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $BCC*$ $$ $$ $$ $$ $$ $$ $$ $$  $$   $$ $$ $$ 19$ 1$
5"M" 1952% 2002%K% $$ $$ $$ $$ BCC*% $$ $$ $$ $$ $$ $$ $$ $ $ $$ $ $ $$   $$   $$ $$ $$ 11$ 1$
6"M" 1940$ 1988$K$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $SK*$ $$ $$ $$ $$ $$ $$ $$ $$ 25$ 1$
7"M" 1943$ 2009$K$ $$ $AK*$ $$ $$ $ $$ $ $ $$   $$   $$   $$   $$   $$ $$ $$ 4$ 1$
8"M" 1938% 2005%K% $$ $$ $$ $$ $$ $AK*
$$$$
SCC*$ $$ $$ $$   $$   $$   $$   $$   $$ $$ $$ 8$ 2$
9"M" 1940$ 2004$K$ $AK*$ $$ $$ $$ $$ $AK*$$$$$ $$ $$ $$ $ $ $$ $ $ $$ $  $$   $$   $$ $$ $$ 9$ 2$
10"M" 1941$
1988$H$$$$$
1996$H$$$
2006$K$
$$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $AK*$$$$$
SCC*$
$$ $$ $$ $$ $$ $$ $$ $$ 25$ 2$
11"M" 1932$$$$$$$$2008†$ 1992$K$
$$ $$ $$ $
SCC*$
$$ $$ $$ $$ $$ $$ $$ $$ $$ $BD*
$$$$$
BCC*$
$$ $
BCC$ $
$$
$ $
$$   $$ $$ $$ 16$ 4$
12"M" 1969$ 1992$K$ $$ $$ $$ $$ $$ $$ $$ $$ $$ 2BCC*
$$$$$
BCC*$ $$ $$ $$ $$ SK$ $$ $$ $$ $$ $$ $$   $$ $$ $$ 21$ 4$
13"M" 1934$ 1981$K$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ SK$$$$$$$$$$BCC$ $$ $$ $$ $$ KA$ $KA*$
$
SCC*$ $$
$
2KA*$$$$$
KA$
$$ $$ $$ $$ (( 32$ 8$
14"M" 1940$ 2000$K$ $$ $$ $$ $$ $$ $AK*$$$$SCC*$
3BCC*$$$
2BCC*$ $$ $$ BCC$
$SK*$$$
BCC$ BCC$ $$  $$   $$   $$   $$ $$ $$ 13$ 10$
15"M" 1946$ 2005$K$ $BCC$ BCC$ $$ $BCC*$ $$
SK$$$$$$$$$$$$$$$$$
2BCC$$
2SCC*$
AK*$$$$$$$$$$$$$$$$$
2BCC*$$
BCC$
$$ $$ $ $ $$   $$   $$   $$   $$ $$ $$ 8$ 12$
16"M" 1948%%%%%%%%2005†% 1993%K%
$$ $$ $AK*$ $$ $$
$2AK*%
2AK*$$$$$$$$$
3SCC*$$$$$$$$$
$$
$
AK*$$$$
KA*$
2AK*$ $$ $AK*
$$$$$$$$
KA*$ $$ $  $$   $$   $$   $$ $$ $$ 12$ 14$
17"M" 1940% 1999%K% BCC*$ SCC*$ $$ $$
1SK*$
SCC*$
2SCC*$
$SK*$$
3AK*$
$$ $$ $$ 2BCC*$$$$$
BCC*$
BCC*$ BCC*$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ $$ 14$ 14$
SK: Seborrheic keratosis; KA: Keratoacanthoma; BD: Bowen’s disease; BCC: Basal cell carcinoma; AK: Actinic keratosis ; SCC: Squamous cell carcinoma 
*lesion in sunlight-exposed body sites. 
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β-HPV DNA detection and genotyping in skin lesions  
The results of β-HPV testing of DNA extracted from the 79 skin lesions are shown in Table 2. As 
already mentioned, in 28 cases multiple biopsy blocks were available corresponding to either the 
core or edges of the lesions. Out of the total 111 formalin fixed paraffin embedded (FFPE) blocks 
analyzed, 94 (85%) were positive for β-HPV DNA. Taking into account  the original lesions from 
which these FFPE blocks were split, overall 69 out of 79 lesions (87%) contained β-HPV DNA. 
Where multiple FFPE blocks were derived from a single lesion, the genotypes found in the core 
and edges of the lesions were the same. The most frequently observed genotypes were HPV 5 and 8 
(both belonging to β1 species), which were found in 51 (65%) and 20 (25%) lesions respectively. 
HPV5 was detected as a single infection in 18 out of 79 lesions (23%) and HPV8 was detected as a 
single infection in two lesions (3%). Infections with two genotypes were found in 13 lesions (16%), 
while more than two genotypes were found in 28 lesions (35%). In the 5 patients who exhibited 
more than 5 lesions, HPV 5 alone or in multiple infections was found in 38 (66%) of the 58 lesions 
developed by these patients.  β1 species, including HPV 5, 8, 14, 24 and 36, accounted for 61 
lesions (77%) which were positive for at least one genotype. Among the genotypes detected from β2 
species, the most frequently observed  were HPV 80 and 38. In patients with multiple lesions, a 
good intra-patient concordance for the genotypes detected among the different lesions developed 
over time was generally observed. 
 
Table 2. β-HPV DNA detection in the different types of skin lesions and in the FFPE blocks in 
which these lesion were splitted. 
 
Skin lesions β-HPV DNA-positive/ total 
FFPE blocks (β-HPV 
DNA-positive/total) 
Lesion FFPE Blocks WL C E 
Total 70/79 94/111 43/51 24/28 27/32 
BCC 25/31 33/44 17/21 8/10 8/13 
SCC 14/14 19/20 8/9 5/5 6/6 
AK 17/19 22/25 11/13 5/6 6/6 
KA 7/7 12/13 1/1 5/6 6/6 
BD 1/1 1/1 1/1 0/0 0/0 
SK 6/7 7/8 5/6 1/1 1/1 
WL, whole lesion; C, core; E, edge 
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Visualization of viral proteins in skin lesions  
The selection of biomarkers used as useful tool to visualize the presence of active infections in 
lesional areas has been deeply investigated for α-HPV types associated with lesions from previous 
studies. The viral E4 and L1 proteins and cellular proliferation marker MCM7 resulted useful 
biomarkers for the visualization of viral life cycle events in α-HPV-induced lesions, including 
cervical tumors associated with high-risk α-HPV infection (Middleton et al. 2003; Borgogna et al. 
2012; Doorbar 2007; Doorbar et al. 2012). In addition it has been reported that detection of E4 is 
helpful for the visualization of active β-HPV infection in skin tumors from epidermodysplasia 
verruciformis (EV) patients, especially in regions where some morphological differentiation of the 
epithelium is still present (Borgogna et al. 2012).  
β-HPVs are known to be transcriptionally active in the skin tumors of patients presenting with 
Epidermodysplasia verruciformis, therefore tissue sections from a benign hyperplastic 
intraepidermal wart-like lesion from an EV patient were used as a positive control for 
immunostaining procedures. In almost all EV lesions it is possible to visualise viral life cycle events 
- already validated for α-HPVs - based on detection of viral protein markers (β-HPV E4 and L1), 
viral genome amplification and cellular proliferation marker MCM7 (Figure 1). The lesion in Figure 
1 shows representative images of tissue sections from a benign wart-like lesion from an EV patient 
displaying unequivocal histological features associated with the infection, including acanthosis and 
the disorganization of the granular layers defined by an abrupt variation in keratoyaline granules. 
The core region of the lesion exhibited typical HPV-induced cytopathic effects in the spinous and 
granular layers, characterized by swollen and irregularly shaped keratinocytes containing enlarged 
hyperchromatic nuclei and pale, granular and often vacuolated cytoplasm with occasional 
perinuclear halos (Cubie 2013; Elder et al. 2005). Cells in this region displayed typical cytoplasmic 
E4 staining. The proliferation marker MCM7, whose expression is normally restricted to the basal 
layer, was also strongly increased compared with the adjacent normal epithelium, being most 
apparent in the basal and upper layers.  
The abnormal expression of MCM7 shows that in order to support viral replication, E4-positive cells 
in the upper layers were driven to re-enter the cell cycle. The lack of E4 positivity in adjacent 
normal epithelium overlapped with a reduction in MCM7 expression, being lowered to the basal 
layer. The positivity for HPV DNA in FISH analysis overlapping the E4 staining confirmed that 
these cells were supporting viral genome amplification. As expected, L1-positive nuclei were 
detected in the more superficial layers of the E4-positive area, indicating completion of the 
productive viral lifecycle with the assembly and release of new infectious particles (Doorbar 2007; 
Doorbar et al. 2012). 
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Figure 1. Distribution of the viral and cellular markers E4, L1, HPV8 DNA and MCM7 in a wart-like lesion 
from an EV patient (elbow). The top panels show (i) an H&E-stained section with the area of interest boxed 
in red (left) and (ii) immunofluorescent staining of the same section. MCM7 is labelled in red and E4 in green 
(right; the white dotted line indicates the basal layer). The region shown in the lower panels corresponds to 
the red square highlighted in the left-hand top panel.  MCM7/E4 co-staining is reproduced (left) and serial 
sections were double stained to demonstrate viral genome amplification by HPV8 DNA-FISH (red) and for 
E4 expression (green) (middle).The right-hand section was  stained with antibodies to L1 (red) (right; the 
white arrows indicate nuclear L1 staining). All sections were counterstained with DAPI (blue) to visualize 
cell nuclei. Scale bars: 100 µm.  
 
 
To investigate whether similar patterns of productive infection seen in EV patients could be 
visualized in the lesions arose in a KTR, all the skin lesions of our cohort were analyzed with the 
viral protein markers. Tissue sections from all 111 FFPE blocks were co-stained for β-HPV E4 and 
L1 to detect viral antigen expression and for MCM7 as a cellular proliferation marker. As the quality 
of DNA extracted from FFPE material is generally poor, affecting the sensitivity and reliability of 
PCR-based assays, immunofluorescent screening was performed on all tissue specimens regardless 
of the results of β-HPV DNA detection.  
Out of the 111 FFPE blocks analyzed, E4-positive cells were found in six blocks (for brevity, 
referred to as IF-positive), as follows: 
- 4 AK (1 from Patient 8 and 3 from Patient 16) 
- adjacent pathological epithelium of 1 SCC (Patient 17) 
- adjacent pathological epithelium of 1 BCC (Patient 15) 
For the first time active infection of β-HPV was found in a skin lesion developed by an organ 
transplant recipient. 
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Patients 5 and 8 received transplants in 2002 and 2005 respectively; Patient 5 developed a single 
lesion (1 BCC, IF-positive) while Patient 8 had 1 SCC prior to the IF-positive AK .  
Patients 16 and 17 received transplants  in 1993 and 1999 respectively and developed 14 skin lesions 
each in their post-transplant period.  
Details of the IF-positive patients along with their skin lesions are summarized in Table 3, reporting 
the specific FFPE blocks (edge, core or whole lesion) where positivity was found and the 
genotyping results relative to these specimens. As expected from the spectrum of the different 
genotypes detected by the polyclonal anti-E4 antibody, all the IF-positive sections harbored 
genotypes belonging to species 1. 
 
Table 3. Characteristics of the IF-positive patients from the KTR cohort and their skin lesions. 
 
Patients Birth date Tx date 
Total  
skin 
lesions 
IF-positive skin lesions (FFPE block) 
years post-tx (y/p-t) 
β-HPV genotypes 
5 (M) 1952 2002 
1 BCC (WL) 
5 y/p-t 
HPV 8 1 BCC 
8 (M) 1938 2005 
2 AK (WL) 
6 y/p-t 
HPV 8, 12, 36 
1 AK 
1 SCC 
16 (M) 1948 (2005†)  1993 
14 AK (WL) 
6 y/p-t 
HPV 25 
AK (E) 
6 y/p-t 
HPV 36, 75 
AK (C) 
8 y/p-t 
HPV 8, 14, 19, 
38, 75 
9 AK  
2 KA  
3 SCC 
17 (M) 1940 1999 
14 
SCC (E)  
5 y/p-t  
HPV 24 
2 SK  
3 AK 
4 SCC 
5 BCC 
 
Tx, transplantation; WL, whole lesion; C, core; E, edge; BCC, basal cell carcinoma; AK, actinic keratosis; 
KA, keratoacanthoma; SCC, squamous cell carcinoma; SK, seborrheic keratosis 
 
Having established the EV staining pattern, all the IF-positive areas identified in the kidney 
transplant recipient’s lesions were analyzed with respect to their histological characteristics and 
staining patterns.  
Representative images are presented below.  
Figure 2 shows one of the two IF-positive areas detected in the adjacent pathological epithelium 
of a BCC from Patient 15 (neck). The epithelial lesion displayed acanthosis and E4/MCM7 and L1 
staining patterns strongly resembled those observed in EV wart-like lesions (Figure 1), with typical 
features of β-HPV productive infection.  
Results 
74 
Figure 3 summarizes immunostaining in Patient 8, focusing on the IF-positive area found in the 
bowenoid AK located next to the SCC on the neck. This area shows clear signs of β-HPV-related 
cytopathic effects, enlarge keratinocytes with pail cytoplasm, with some cells displaying 
pleomorphism and nuclear atypia. Both early and late viral markers of β-HPV infection are present, 
suggesting the presence of β-HPV productive infection. 
 
 
 
Figure 2. Distribution of the viral and cellular markers E4, L1 and MCM7 in a basal cell carcinoma from a 
kidney transplant recipient (Patient 5, neck). The top panel shows the scanned image of H&E stained section 
(scale bar: 1000 µm) where the blue circle indicates the BCC core region and the red square region of interest 
in the adjacent pathological epithelium. The area shown in the lower panels (scale bars: 100 µm) corresponds 
to the red square highlighted in the top panel. The same section was double stained using antibodies to E4 
(green) and MCM7 (red) (middle image) while an adjacent section was stained with antibodies to L1 (red) 
(right image; the white arrows indicate nuclear L1 staining). All sections were counterstained with DAPI 
(blue) to visualize cell nuclei.  
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Figure 3. Distribution of the viral and cellular markers E4, L1 and MCM7 in a bowenoid actinic keratosis 
from a kidney transplant recipient (Patient 8, neck). The top two images (scale bars: 1000 µm) show H&E 
stained sections; the right-hand panel demostrating the AK with the area of interest boxed in red, while the 
left-hand panel illustrates a nearby SCC. The region shown in the lower panels (scale bars: 50 µm) 
corresponds to the red square highlighted in the right-hand top panel. The same section was double stained 
using antibodies to E4 (green) and MCM7 (red) (middle picture) and a serial section was stained with 
antibodies to L1 (red) (right; the white arrows indicate nuclear L1 staining). All sections were counterstained 
with DAPI (blue) to visualize cell nuclei.  
 
 
A total of 3 hypertrophic AK developed from the same patient (Patient 16) are shown in Figures 
4-6.  
Figure 4 shows an AK (hand) with an unambiguous area of positivity found in an epithelial crevice, 
where disruption of the granular layer was clearly evident alongside parakeratosis, a histological 
feature indicative of HPV infection (Elder et al. 2005). In this case, it was possible to perform FISH 
analysis for the single genotype found, specifically HPV 25. FISH-positive nuclei neatly overlapped 
with some E4-positive cells in the cytoplasm, while L1 positivity was confined to the upper 
epithelial layers and some parakeratotic nuclei. 
The IF-positive region reported in Figure 5 was found in the pathological edge of an AK (face) and 
showed the typical staining pattern and cytopathic effects of productive β-HPV infection. The AK of 
Figure 6 (hand) showed an IF-positive area corresponding to a highly parakeratotic epithelium that 
abruptly changed to normal orthokeratosis on both sides; as expected from the high grade of 
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parakeratosis, many L1-positive nuclei were found above the E4-positive cells. Consistent with the 
typical staining pattern of EV wart-like lesions shown in figure 1, MCM7 expression was increased 
in all the IF-positive areas being present in the basal layer and above. This pattern of staining 
decreased with the onset of E4 expression, although an overlap region was well apparent where 
E4/MCM7 double positive cells were found (see especially Figure 5). 
 
 
 
Figure 4. Distribution of the viral and cellular markers E4, L1, HPV25 DNA and MCM7 in a hypertrophic 
actinic keratosis from a kidney transplant recipient (Patient 16, hand). The top panel (scale bar: 1000 µm) 
shows an H&E stained section with the area of interest boxed in red. The region shown in the lower panel 
(scale bars: 50 µm) corresponds to the red square highlighted in the top panel. Serial sections were double 
stained using antibodies to E4 (green) and MCM (red; second image). Sections were also double stained to 
show viral genome amplification HPV25 DNA-FISH (red) with E4 expression (green; third image); and also 
stained with antibodies to L1 (red) (fourth panel; the white arrows indicate nuclear L1 staining). All sections 
were counterstained with DAPI (blue) to visualize cell nuclei.  
 
 
 
 
 
 
Results 
77 
 
 
Figure 5. Distribution of the viral and cellular markers E4, L1, HPV25 DNA and MCM7 in a hypertrophic 
actinic keratosis from a kidney transplant recipient (Patient 16, face). The top two micrographs (scale bars: 
1000 µm) show H&E stained sections of the core region of the lesion (left) and its edge (right) with the area 
of interest boxed in red. The middle panel (scale bars: 200 µm) shows the histology (H&E staining) of the 
area from the edge where viral markers were expressed, highlighted in the red square (left), and an overall 
picture of immunofluorescent staining (E4 in green; MCM7 in red) of the same tissue section (right; the white 
dotted line indicates the basal layer). The lower panel (scale bars: 100 µm), shows a magnified image of 
MCM7/E4 co-staining  (left). Serial sections were stained with antibodies to L1 (red) (right; the white arrows 
indicate nuclear L1 staining). All sections were counterstained with DAPI (blue) to visualize cell nuclei. 
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Figure 6. Distribution of the viral and cellular markers E4, L1, HPV25 DNA and MCM7 in a hypertrophic 
actinic keratosis from a kidney transplant recipient (Patient 16, hand). The top panel (scale bar: 100 µm) 
shows an H&E stained section, with a magnified insert (scale bar: 400 µm) illustrating a region of positive 
parakeratotic epithelium that abruptly changes to normal orthokeratosis on both sides. The region shown in 
the lower panel (scale bars: 50 µm) corresponds to the red square highlighted in the insert in the top panel. 
The first image (left) shows H&E staining of this area. Adjacent serial sections were immunostained using 
antibodies to E4 (green) and MCM7 (red; middle image) and L1 (red; right hand image). All sections were 
counterstained with DAPI (blue) to visualize cell nuclei. 
 
 
 
 
Adjacent to the pathological epithelium of a SCC from Patient 17 (ear), a clear positive area was 
observed between two hair follicles (red box top right panel, Figure 7). Here, the cytopathic effect 
was remarkable consistent to that generally found in EV wart-like lesions; many E4-positive cells 
were present, as well as superficial L1-positive nuclei.  
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Figure 7. Distribution of the viral and cellular markers E4, L1 and MCM7 in the adjacent pathological 
epithelium of a squamous cell carcinoma from a kidney transplant recipient (patient 17, ear). The top panel 
shows H&E stained images of the SCC core region (left; scale bar: 500 µm) and its edge (right) with the area 
of interest boxed in red (scale bar: 1000 µm). The region shown in the lower panel (scale bars: 50 µm) 
corresponds to the red square in the top right-hand micrograph. The left hand image shows an H&E stained 
section with a magnified insert (scale bar: 20 µm) showing the cytopathic effect. Serial sections were double 
immunostained using antibodies to E4 (green; middle image) and  to L1 (red; right hand image). All sections 
were counterstained with DAPI (blue) to visualize cell nuclei. 
 
 
Overall, the cytological detail of histologically stained sections and immunostaining patterns for 
viral E4 and L1 proteins and cellular proliferation marker MCM7 found in the IF-positive KTR skin 
lesions are strikingly similar to those typically observed in EV wart-like lesions, exemplified in the 
representative images shown in Figure 1, associated with β-HPV productive infection. 
H&E stained sections of all the tissue sections, which did not demostrate viral marker expression, 
were carefully screened for the presence of any HPV-related cytophatic effects. Consistently with 
the absence of detectable viral activity, no such features were found in any of these negative 
specimens. 
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HPV8 Transgenic mice 
 
 
 
 
Phenotype of mice expressing HPV8 early genes 
To define the influence of βHPV gene 
expression on keratinocytes differentiation, the skin 
of βHPV8 transgenic mice was investigated. This 
in-vivo model expresses the complete early region 
genes under the control of the epithelia specific 
K14 promoter. Previous studies have shown that in 
this model, 91% of HPV8-transgenic mice 
developed single or multifocal benign tumours such 
as papillomatosis, acanthosis, hyperkeratosis and 
epidermal dysplasia; 6% of them also developed a 
squamous cell carcinomas (Schaper et al. 2005). 
Morphogical and histological characteristics of 5 
wild type mice and 5 HPV8 transgenic mice were 
analysed revealing that the skin of βHPV8 
transgenic mice was thicker than wild type 
littermates with mean thicknesses of ears (0.67 vs 
0.42 mm) and tails (3.51 vs 3.39 mm). Consistent 
with the observation of thicker skin in our 
transgenic model. H&E staining of sections from transgenic mice showed taller keratinocyte 
columns in adult βHPV8 transgenic mice hair follicle and adjoining interfollicular epidermis, 4.20 ± 
0.47 vs 2.00 ± 0.00 cells and 3.83 ± 0.49 vs 1.5 ± 0.43 cells respectively (n=5). However, the weight 
and tail length were not significantly different between transgenic mice and wild type controls.  
 
 
 
 
 
 
A 
B 
Figure 8. Comparison between 28 weeks old wild type 
(A) and HP8 transgenic mice (B). In transgenic mice 
tumours spontaneously developed during 5 weeks are 
clearly visible and diffusely spread 
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Visualization of keratinocyte stem cell marker phenotypes in transgenic and wild type mice 
 
The epidermal whole mount protocol was established while 
working in the laboratory of Dr G. Patel (European Cancer Stem 
Cell Research Institute, Cardiff University, UK) as a visiting 
scientist, over a period of 7 months as part of the Ph.D program. 
Figure 9 shows representative epidermal whole mount samples of 
wild type and HPV8 Transgenic mice stained with toluidine blue. 
As illustrated in these images, the epidermal whole mount protocol 
led to a complete visualization of all the keratinocyte populations all 
along the hair follicle. 
As already mentioned, there are at least 4 keratinocyte stem cell 
populations in the hair follicle that can recreate the entire 
interfollicular epidermis and hair follicle. However, in homeostasis, 
the different populations display different functions. LGR5+ cells in 
the hair bulb and lower portion of the bulge support hair shaft 
formation. CD34 and K15 positive cells of the bulge are involved 
in hair cycling, supporting regrowth of the hair follicle during the 
anagen phase. LGR6 positive cells, at the entry point of the 
sebaceous gland and within the sebaceous gland maintain sebaceous gland turnover. Lrig 1 positive 
cells at the junctional zone support turnover of the infundibulum and adjacent overlying epidermis. 
To determine which population of hair follicle keratinocyte stem cells was expanded in βHPV8 
transgenic mice compared to wild type littermates, epidermal whole mount samples were co-stained 
with the KSC markers CD34, K15, LGR6, LGR5 and Lrig1 and with the proliferation marker Ki67 
(Figure 10). So far unfortunately it wasn’t possible to obtain a reliable LGR5 labelling. 
Hair follicle size, and the positive areas of all the KSC markers were analysed in both wild type 
and transgenic mice using ImageJ software (Figure 10). No difference in hair follicle length was 
observed, however the width and therefore overall area of the hair follicles was greater in the 
transgenic mice correlating with expansion of the Lrig1+ area. The mean area of the hair follicle 
Lrig1+ population was markedly increased in the βHPV8 transgenic mice compared to wild type 
mice (23,845+/-13,480 vs 14,907+/- 3,793 µm2, p<0.001), compared to the CD34+ (8,356+/-1,465 
vs 8,077+/- 1,510 µm2, p=NS), and LGR6+ population (60,250 +/- 9,972 vs 49,216 +/- 13,540 µm2, 
p=0.01). In line with these findings the hair follicle keratinocyte stem cell proliferation, validated 
with the marker of proliferation Ki67, was higher within the Lrig1+ (69 vs 55%, p<0.001), 
WT HPV8 
Figure 9. Epidermal whole mount 
samples of wild type and HPV8 
Transgenic mice stained with 
toluidine blue. (scale bar: 100 µm) 
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compared to the CD34+ (1 vs 1%), and LGR6 (29 vs 40%) populations, of βHPV8 transgenic 
compared to wild type mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lrig%1 LGR6 
CD34 K15 
βHPV8 WT 
STEM%CELL%MARKER%Ki67!DAPI 
βHPV8 WT 
βHPV8 WT βHPV8 WT 
Figure 10. Distribution of keratinocyte stem cell markers CD34, K15 LGR6 and Lrig1 (green) 
co-stained with the marker of proliferation Ki67 (red), in whole mount analysis comparing 
wild type and transgenic mice. In all the sections of transgenic mice is possible to visualize an 
increase in proliferation overlapping the Lrig1 positive area. The red arrow in the lower right 
hand panel shows the increased Lrig 1 positive area in transgenic mice. All sections were 
counterstained with DAPI (blue) to visualise cell nuclei. 
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Conclusions 
Collectively, the results obtained in the KTR study cohort indicate that detection of β-HPV 
infection at the DNA level does not prove any viral activity in the context of the lesional epithelium. 
Immunohistochemical screening for viral markers revealed active β-HPV infection in precancerous 
lesions (4 AK) and the adjacent pathological epithelium of high-grade lesions (1 BCC and 1 SCC) 
from the KTR cohort, suggesting that these viruses are actively implicated in the pathogenic 
mechanisms underlying skin carcinogenesis in the immunosuppressed setting of organ transplant 
recipients. Furthermore, results obtained using an in-vivo model of HPV8 transgenic mice suggest 
an interaction between β-HPV gene expression and a specific keratinocyte stem cell population. In 
accordance with a previously published report (Schaper et al. 2005), an increase in keratinocyte 
proliferation was demonstrated in the HPV8 model. Despite the expression of the transgene 
throughout the basal layer of skin and appendages, the whole mount protocol revealed that 
keratinocyte proliferation in βHPV8 transgenic mice, when compared to that in wild type mice, was 
localized only around the hair follicle isthmus, infundibulum and adjacent epidermis and 
overlapping the same area with the increased expression of the stem cell marker Lrig 1. 
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DISCUSSION 
 
 
 
 
To our knowledge, this is the first study in which the association between skin lesions and β-
HPV infection has been assessed at both the DNA level by PCR analysis and the protein level by 
immunofluorescence analysis. The first aim of the study was to determine whether detection of 
transcriptionally active β-HPV infection and active β-HPV replication could also be observed in 
cutaneous lesions from kidney transplant recipients (KTRs), as already defined in skin tumors from 
epidermodysplasia verruciformis (EV) patients, who display a high susceptibility of β-HPV 
infection associated with the development of disseminated wart-like lesions with a high propensity 
for malignant progression (Borgogna et al. 2012). The second aim was addressed to investigate the 
influence of HPV gene expression on keratinocytes differentiation in in-vivo model, using the β-
HPV transgenic mice, expressing the complete early region of HPV8; described to develops 
spontaneously skin cancer in the absence of any additional co-carcinogenic treatments (Schaper et 
al. 2005; Akgül et al. 2006; Pfister 2003).  
 
KTRs, affected by an acquired immunodeficiency status, were compared with the primary 
immunodeficiency setting of EV patients because they share the following two main features:  
- A status of chronic immunosuppression, which may favor persistence or reactivation of latent 
skin-tropic viruses including β-HPV;  
- The high risk of developing multiple skin tumors (Euvrard et al. 2003; Wisgerhof et al. 2010). 
These commonalities are also valid for patients affected by primary immunodeficiencies in general 
(Leiding & Holland 2012). 
In addition, in this study the EV model served as an important tool for optimizing the staining 
procedures for β-HPV E4 and L1 proteins and was used as a positive control when examining KTR 
tissue sections. A polyclonal antibody recognizing the E4 protein from β1 species was used 
alongside a polyclonal antibody raised against a highly conserved region of the β-HPV L1 protein.  
From the cohort of KTRs a total amount of 111 FFPE blocks were obtained, previously collected 
from 79 skin lesions. Due to the different size of the lesions the samples were either split in more 
sections or maintained in a single intact. For 51 lesions a single block was available, denominated 
“whole lesion”; 28 lesions were sectioned in two or more blocks, corresponding to the core and 
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edges of the lesion. All lesions were excised from 17 KTRs (16 male and 1 female), receiving 
transplants between 1998 and 2009.  
The initial PCR analysis demonstrated that β-HPV DNA was highly present in these specimens, 
with 94 FFPE blocks (85%) and 69 original lesions (87%) resulting positive. Multiple infections 
were observed in 41 lesions (52%), and at least one genotype belonging to the b1 species was found 
in 79 of the 111 blocks analyzed by PCR (71%). 
Immunofluorescence analysis revealed positivity for viral markers in 6 FFPE blocks, 
corresponding to 4 actinic keratoses (AK) and the adjacent pathological epithelium of 1 basal cell 
carcinoma (BCC) and 1 squamous cell carcinoma (SCC). Positivity for β-HPV E4 was found in the 
context of the disorganized epithelium in the AK lesions, while in the 2 high-grade tumors they 
were localized to the lesional area surrounding the core region of the lesions. In all these specimens, 
the β-HPV E4 protein displayed the expected cytoplasmic localization in the mid-superficial layers 
of the epithelium accompanied by an elevation of the cellular proliferation marker MCM7 in the 
basal and suprabasal layers; the disappearance of E4-positivity in the adjacent normal epithelium 
constantly overlapped with a reduction in MCM7 expression, which was restricted to the basal 
layer. These findings support the hypothesis that β-HPV replication drives the cells above the basal 
layer to re-enter the cell-cycle in order to support viral genomic amplification; consistently with this 
observation, FISH-positive nuclei were found in some of the E4-positive cells in one AK lesion. As 
further proof that the productive viral lifecycle was being completed, all the E4-positive areas 
showed expression of the major coat protein L1 which also occurred in a subset of E4-positive cells 
in the upper layers. This is fully consistent with what has been seen in the case of other PV types 
including α-HPVs, where the onset of viral genomic amplification coincides closely with the 
expression of cytoplasmic E4 and nuclear L1 in some very superficial cells during productive 
infection (Doorbar 2007; Doorbar et al. 2012; Middleton et al. 2003). All the positive lesions 
displayed histological signs associated with HPV infection, including the typical cytopathic effect 
and parakeratosis (Cubie 2013; Elder et al. 2005); in one highly differentiated AK lesion, many L1 
positive nuclei were detected and most of them localized to the thick upper parakeratotic layers. 
 
A common trait of cancers with a well-documented viral etiology is their high incidence in 
immunosuppressed individuals (Piselli et al. 2009; Schulz 2009; Grulich et al. 2007). Based on the 
relevance that non-melanoma skin cancer (NMSC) is the most prevalent type of malignancy in the 
immunosuppressed setting of organ transplant recipients (OTRs) undergoing immunosuppressive 
therapy, one would expect that viruses may contribute to this widely reported increased 
susceptibility and incidence (Aldabagh et al. 2013). The detection of active β-HPV infection in EV 
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patients provided an important new insight into the viral oncogenesis of NMSC which might be 
extendable to further subsets of patients with impaired immune function including individuals with 
other primary immunodeficiencies and particularly long-lasting iatrogenically immunosuppressed 
subjects, such as OTRs. Despite many efforts, direct evidence of active β-HPV infection in skin 
lesions from non-EV patients were still missing and the major criticism against a direct involvement 
of these viruses in the pathogenesis of NMSC is that they do not seem to be maintained in high-
grade tumors, such as SCC.  
To date, the evidence suggesting a causal role of β-HPVs in skin carcinogenesis has been tainted by 
the main following reasons:  
- It is possible to detect viral DNA in normal skin in both healthy and immunosuppressed 
individuals; 
- Viral genome copy number is present in much less than one genome copy per tumor cell in non-
EV skin lesions, and always in episomal form;  
- Viral transcripts have not been identified by high-throughput mRNA sequencing in non-EV 
SCC; 
- β-HPV E6/E7 oncoproteins exhibit different properties and a lower transforming potential 
compared to high-risk α-HPV oncoproteins (Akgül et al. 2006; Pfister 2003; Feltkamp et al. 
2008; Sarah T Arron et al. 2011; Aldabagh et al. 2013). 
Alongside the fact that ubiquitous β-HPV DNA carriage does not necessarily indicate active 
infection, these issues have created and so far maintained a state of uncertainty about the causative 
role of β-HPVs in non-EV skin cancer. Although the present study does not directly demonstrate a 
causal role of these viruses, the detection of β-HPV E4 and L1 expression in 4 AK, widely regarded 
to be SCC precursors or in situ carcinoma, and the adjacent pathological epithelium of 1 SCC and 1 
BCC, clearly shows that β-HPVs do actively replicate in OTR lesional skin. 
The findings obtained in this study for KTR skin lesions, showing active β-HPV infection in 
precancerous lesions and in the vicinity of malignant tumors, are fully compatible with a role of 
these viruses in the initial phases of skin carcinogenesis at least in the OTR immunosuppressed 
setting. These data are consistent with previous findings showing that the highest β-HPV loads are 
present in AK rather than in SCC, suggesting that their persistence may not be necessary for the 
maintenance of the transformed phenotype (Weissenborn et al. 2005). All these evidences are 
consistent with the “hit and run” model of β-HPV-induced skin carcinogenesis; according to this 
model, the viruses play a transient role in the early steps of the process being important for tumor 
initiation and progression, probably acting as co-factors enhancing the carcinogenic potential of UV 
damage, but they are likely not to be necessary for tumor maintenance. Consistent with a causal role 
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of β-HPVs in the initial stages of the disease, E4-positive areas were clearly visualized in 1 AK 
located adjacent to 1 SCC in the neck region of a patient. Furthermore the observed stimulation of 
basal and suprabasal cell proliferation shown by MCM7 expression in the upper epithelial layers of 
all the E4–positive areas may contribute, in association with other transforming agents such as UV 
irradiation, to the transformation process without necessarily being maintained in the more 
advanced disease (Peh & Doorbar 2005; Doorbar 2005; Doorbar et al. 2012; Akgül et al. 2006; 
Feltkamp et al. 2008). In this study was confirmed the crucial role of UV light in skin 
carcinogenesis, as a substantial proportion of the lesions developed by KTR cohorts were located in 
sun-exposed body sites. 
Assuming that viral replication is more active at very early phases of carcinogenesis and perhaps 
when lesions are not yet even clinically evident, it is reasonable to propose that when lesions are 
removed, especially in more advanced stages, only some residual areas are detectable that exhibit 
viral replication. It is also worth mentioning that the areas of positivity were usually found in 
lesions which were originally split in more than one FFPE block; this procedure is currently applied 
when the surgical specimen is quite big and the different areas of the lesion are macroscopically 
evident, as it occurs when the erythematous area surrounding the tumor is also surgically removed.  
This context is defined as field cancerization. These assumptions might explain the low percentage 
of positivity found in this kind of study and the need of more thorough investigation of the 
perilesional skin where the likelihood of finding active β−HPV infection should be higher. 
Furthermore the findings achieved in this study shows how the mere presence of viral DNA in a 
lesion does not necessarily indicate that the virus is driving or contributing to tumor development or 
progression. Detection methods allowing direct visualization of viral replication and transcriptional 
activity, like FISH analysis for viral genomic amplification and staining for β-HPV E4 and L1 
proteins as done in this study, are fundamental to demonstrate biologically significant viruses in the 
context of lesional tissues. As these methods are getting compelling evidence that reactivation of 
ubiquitous viruses, such as β-HPVs in the OTR setting, may be actively involved in NMSC 
initiation and progression, more efforts should be addressed to visualize active viral replication and 
protein expression rather than limiting the analysis at the DNA level.  
 
To date are present a reasonable amount of studies aimed to clarify the mechanism that lead 
HPVs to a persistent infection and lesion formation. 
The general hypothesis is that lesion formation begins with the infection of a basal stem cell (rather 
than a basal transiently amplifying cell) and that the longevity of the stem cells is a key factor in the 
formation of a persistent lesion, with these cells being a reservoir for the infection. Cancer 
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development requires the virus to escape the host immune response over an extended period to lead 
the accumulation of genomic and genetic abnormalities. High-risk α-HPV chronic infections are 
characterized by long persistence in the slow-cycling epithelial stem cells, and this is a condition 
sine qua non for the development of HPV-associated malignancy. 
Several studies have reported the ubiquitously presence of these β-HPV types on the body 
surface in immunosuppressed individual and in general population, with greater carriage in sun-
exposed sites (e.g. forehead) that in sun-protected skin when their presence were detected in 
plucked hairs and skin swabs. They appear to establish a reservoir of infection in the follicular stem 
cells of hair bulbs, which are thought to be an immune privileged site protecting them from immune 
clearance and therefore enabling the persistence of multiple β-HPV types. 
The capability to establish a reservoir of infection in the keratinocyte stem cell and to drive the 
cells to re-enter the cell-cycle in order to support viral genome amplification, represent the 
assumption upon which is based the second aim of this study. This aim was addressed to investigate 
the influence of βHPV gene expression on keratinocytes differentiation, and to pursuit this purpose 
it has been chosen the transgenic mice model expressing the entire early region of HPV8; so far the 
first model capable to develops spontaneously skin cancer in the absence of any additional co-
carcinogenic treatments (Schaper et al. 2005; Akgül et al. 2006; Pfister 2003). To investigate the 
keratinocyte stem cells (KTCs) in the hair follicle were selected 4 different stem cell populations; 
which can recreate the entire hair follicle but in homeostasis support the turnover of different areas 
along all the hair follicle (Ghadially 2012; Cotsarelis 2006; Schepeler et al. 2014; Hsu et al. 2011; 
Snippert et al. 2010; Page et al. 2013). To distinguish the different population immunofluorescent 
staining for the KSC markers CD34, K15, LGR6, LGR5 and Lrig1 in correlation with the 
proliferation marker Ki67 have been established. So far unfortunately it wasn’t possible to obtain a 
reliable LGR5 labelling.  
The analysis of epidermal whole mount samples from both HPV8 transgenic mice and wild type 
littermates shows no difference in hair follicle length, however the width and so overall area of the 
hair follicles was greater in the transgenic mice correlating with expansion of the Lrig1+ area. The 
mean area of the Lrig1+ population was markedly increased in the βHPV8 transgenic compared to 
wild type mice (23,845 vs 14,907 µm2), compared to the CD34+ (8,356 vs 8,077 µm2), LGR6+ 
(60,250 vs 49,216 µm2). In line with these findings the hair follicle keratinocyte stem cell 
proliferation was greater within the Lrig1+ (69 vs 55%), compared to the CD34+ (1 vs 1%), and 
LGR6 (29 vs 40%) populations, of βHPV8 transgenic compared to wild type mice. 
 These data suggesting that the early region genes of βHPV8 specifically target Lrig1+ cells, 
forcing the keratinocyte stem cells to proliferate and leading to an expansion of the keratinocytes 
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both in the hair follicle infundibulum and in the overlying interfollicular epidermis. The continuous 
proliferation of the Lrig1 population would compete with the normal epidermal keratinocytes and 
may result in its persistence over the entire epidermis, leading to the development of the field 
cancerization.  
In summary, this work shows that careful detection of β-HPV activity markers (gene products 
and viral genomic amplification) at the single cell level allows to visualize their sites of replication, 
especially in intraepidermal precursor lesions and the marginal zones of more advanced disease. 
Also reveals the possible influence of the viral gene expression on the normal keratinocyte 
differentiation; identifying as target the specific KSC population expressing the Lrig1 marker in the 
β-HPV8 in-vivo model. Next step will be to validate these findings in human, looking for an Lrig1 
or equivalent stem cell population expansion.  
Further research are required to improve our knowledge of natural β-HPV infection and 
reactivation which will help understand how it is influenced by the epithelial site, UVB exposure 
and the immune system.  
The viral lifecycle biomarkers analyzed could potentially be validated as diagnostic and 
prognostic tools for the assessment of the risk of keratinocyte carcinoma development in 
immunosuppressed patients like OTRs based on the activity status of these viruses. That would be a 
good starting point for the planning of adequate preventive strategies. 
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